US Pat. No. 10,391,107

COMPOSITIONS AND METHODS FOR SUPPRESSING OR REDUCING SYSTEMIC IMMUNE RESPONSE IN A SUBJECT

The Trustees of the Unive...

1. A method of increasing systemic regulatory T cell (Treg) levels in a subject, the method comprising:topically administering to the subject a pharmaceutically effective amount of a composition consisting essentially of a vitamin D3 analog, wherein the vitamin D3 analog is 26,27-cyclo-22-ene-1?,24S-dihydroxyvitamin D3 (MC903 or calcipotriol) and at least one pharmaceutically acceptable excipient,
whereby systemic Treg levels are increased in the subject, wherein the vitamin D3 analog is the only biologically active agent administered to the subject; and
wherein the subject is afflicted with an inflammatory disease selected from the group consisting of type I diabetes, type II diabetes, atherosclerosis, multiple sclerosis, and rheumatoid arthritis.
US Pat. No. 10,392,646

DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF AMINOACIDOPATHIES

University of Maryland, C...

1. A biosensor comprising:at least one electrically conductive support, the at least one electrically conductive support attached to a hydrogel, the hydrogel comprising at least one electron mediator, at least one reduction agent, and at least one metabolic enzyme from a thermophilic bacterial cell or functional fragment thereof, wherein the hydrogel comprises alginate; and
an amperometer and/or voltmeter operably connected to the at least one electrically conductive support;
wherein the at least one electrically conductive support comprises a phenylalanine dehydrogenase or functional fragments thereof; and
wherein the phenylalanine dehydrogenase or functional fragment thereof comprises at least about 70% sequence identity to SEQ ID NO:1 or SEQ ID NO:2.
US Pat. No. 10,391,108

PHARMACEUTICAL TETRACYCLINE COMPOSITION FOR DERMATOLOGICAL USE

BioPharmX, Inc., San Jos...

1. A topical composition, comprising:minocycline,
a divalent cation,
a sulfite compound, and
a solvent;whereinthe minocycline is dissolved in the composition; and
the relative concentration of 4-epi-minocycline in the composition is less than 5.0% after storage at 40° C. in a sealed glass vial for 4 weeks.
US Pat. No. 10,391,109

USE OF ZOLEDRONIC ACID TO PREPARE DRUG TREATING FATTY LIVER DISEASE

NANJING UNIVERSITY, Nanj...

1. A method of treating fatty liver disease in a human, comprising administering zoledronic acid to treat the fatty liver disease; wherein a dosage range of the zoledronic acid is from 50 ?g/kg to 200 ?g/kg per intravenous injection, once every two days.
US Pat. No. 10,390,598

ELASTIC CLOTHING OR ACCESSORY TREATED WITH MICROENCAPSULATED SUBSTANCE AND HAVING CONSUMER-ACTIVATED PULL MECHANISM

Conscious Creations, LLC,...

1. An apparatus comprising:an elastic band that includes an elastic core that is surrounded by a fabric;
microencapsulated substance applied to the fabric of the elastic band, wherein the elastic band has a wet pick up of at least 50%;
a graspable pull mechanism attached to the elastic band;
wherein microencapsulated substance is released when the pull mechanism is pulled to stretch the elastic band from a natural relaxed state or a semi-stretched state, and further wherein the pull mechanism is attached to the elastic band so that it can be moved prior to the consumer pulling on the pull mechanism, and consequently activating the microencapsulated substance in a variety of regions of the elastic band.
US Pat. No. 10,391,110

COMPOSITION FOR PREVENTING OR TREATING VASCULAR LEAK SYNDROME

Intelligent Synthetic Bio...

1. A method for treating vascular leakage syndrome comprising administering a composition comprising ginsenoside F1, ginsenoside Rh1, or a combination thereof to a subject having vascular leakage syndrome.
US Pat. No. 10,392,649

BIOSENSORS THAT DETECT NAD+

1. A recombinant nicotinamide adenine dinucleotide (NAD+) biosensor polypeptide comprising:a first NAD+ dependent DNA ligase adenylation domain fragment, the first fragment comprising an amino acid sequence derived from an N-terminal portion of the DNA ligase adenylation domain;
a second NAD+ dependent DNA ligase adenylation domain fragment, the second fragment comprising an amino acid sequence derived from a C-terminal portion of the DNA ligase adenylation domain; and
a fluorescent protein;
wherein the fluorescent protein is located between the first NAD+ dependent DNA ligase adenylation domain fragment and the second NAD+ DNA ligase adenylation domain fragment;
wherein the first fragment is at least 60 amino acids in length, is derived from the N-terminal 80 amino acids of the DNA ligase adenylation domain, and comprises a sequence at least 95% identical to SEQ ID NO: 1 (LigA 2-70); and
wherein the second fragment is at least 200 amino acids in length, is derived from the C-terminal 260 amino acids of the DNA ligase adenylation domain, and comprises a sequence at least 95% identical to SEQ ID NO: 2 (LigA 78-317).
US Pat. No. 10,392,650

RAPID, LOW-SAMPLE-VOLUME CHOLESTEROL AND TRIGLYCERIDE ASSAYS

Theranos IP Company, LLC,...

1. A reagent for use in a cholesterol assay, said reagent comprising a lipoprotein solubilization agent, lipoprotein interactant, and a buffer, wherein said lipoprotein interactant is present at a concentration level that provides for conversion of high density lipoprotein cholesterol (HDL-C) to a measureable colored product at a substantially different rate than for conversion of low density lipoprotein cholesterol (LDL-C) to a measureable colored product and at a substantially different rate than for conversion of very low density lipoprotein cholesterol (VLDL-C) to a measureable colored product when said reagent is used in a cholesterol assay;wherein the lipoprotein interactant comprises a negatively charged polysaccharide and a divalent cation, or a salt thereof, in a ratio of between 0.003 to 0.007.
US Pat. No. 10,392,651

PROCESSED BIOLOGICAL SAMPLE STORAGE

GE Healthcare UK Limited,...

1. A fluidic device for processing a biological sample in order to extract and process nucleic acids contained in said sample and for subsequently amplifying said extracted and processed nucleic acids, said device including a processed sample storage archive area comprising an absorbent solid substrate treated with at least one nucleic acid stabilizing reagent or reagent mix, said substrate allowing the generally dry and stabilized storage of said processed extracted and/or amplified nucleic acids.
US Pat. No. 10,391,113

COMPATIBLE COMPOSITION CONTAINING CHINESE MEDICINE CICHORIUM GLANDULOSUM BOISS ET HOUT AS LIPID-LOWERING ACTIVE INGREDIENT

NANJING RUIYING RUNZE BIO...

1. A method of treating a lipid metabolism disorder disease, the method comprising administering to a patient in need a compound pharmaceutical composition, comprising pharmaceutical active ingredients and pharmaceutically accepted carrier, wherein the pharmaceutical active ingredients consist of quercetin-3-O-?-D-glucuronide, isoquercitrin and quercetin at a molar ratio of 1.1-2.4:1.3-3.3:1.2-3.1, wherein the lipid metabolism disorder disease is selected from the group consisting of obesity, fatty liver, atherosclerosis and hyperlipoprotememia.
US Pat. No. 10,391,114

THERAPEUTIC COMBINATIONS OF CURCUMINOIDS AND FLAVONOIDS

Primus Pharmaceuticals, I...

1. A unit dosage form in the form of an orally administered tablet or capsule comprising:a) one or a combination of flavonoids consisting of baicalin and catechin; and
b) a curcuminoid selected from curcumin.
US Pat. No. 10,391,115

ANTICANCER ADJUVANT COMPOSITION CONTAINING RIP3 EXPRESSION PROMOTER AS ACTIVE INGREDIENT, METHOD FOR SCREENING FOR ANTICANCER ADJUVANT ENHANCING SENSITIVITY OF ANTICANCER DRUG BY PROMOTING RIP3 EXPRESSION, AND METHOD FOR MONITORING SENSITIVITY OF ANTICANC

AJOU UNIVERSITY INDUSTRY-...

1. A method for enhancing chemotherapeutic drug sensitivity of cancer cells in a subject in need of cancer treatment, the method comprising:administering to the subject a therapeutically effective amount of an RIP3 protein expression inducing agent or activator as an anticancer adjuvant;
wherein the anticancer adjuvant enhances chemotherapeutic drug sensitivity in the cancer cell; and
wherein the RIP3 protein expression inducing agent or activator is a 5-aza-2?-deoxycytidine or a 5-azacytidine.
US Pat. No. 10,391,116

POLYVALENT RNA-NANOPARTICLE COMPOSITIONS

NORTHWESTERN UNIVERSITY, ...

1. A nanoparticle composition comprising:at least two ribonucleic acid (RNA) polynucleotides functionalized to the nanoparticle, wherein at least two RNA polynucleotides have a different sequence and form a duplex under conditions appropriate to form the duplex, wherein the duplex is located distal and not proximal to the nanoparticle, and the distance of the duplex from the nanoparticle is equivalent to at least 10 nucleotides; and
wherein each RNA polynucleotide comprises an additional polynucleotide having a sequence that forms the duplex with the RNA polynucleotide under conditions appropriate to form the duplex, the duplex providing a polypeptide interaction site;
each additional polynucleotide having at least one domain sufficiently complementary to a sequence in a target polynucleotide to permit hybridization, and hybridization of each additional polynucleotide to the sequence in the target polynucleotide creates a substrate site recognized by a polypeptide; and
wherein the nanoparticle composition binds to different target polynucleotides that encode different gene products.
US Pat. No. 10,392,655

METHODS OF REDUCING DENSITY-DEPENDENT GC BIAS IN AMPLIFICATION

ILLUMINA CAMBRIDGE LIMITE...

1. A method for reducing density-dependent GC bias and/or nucleic acid damage in bridge amplification of a double-stranded DNA template on a surface comprising:(a) denaturing the double-stranded DNA template with a first solution comprising formamide and at least one type of dNTP to produce single-stranded DNA template strands;
(b) annealing the single-stranded DNA template strands to oligonucleotide primers bound to the surface; and
(c) extending the oligonucleotide primers by replacing the first solution with a solution comprising a polymerase and a mixture of different dNTPs, whereby the oligonucleotide primers bound to the surface are fully extended; and
(d) repeating steps (a)-(c) at least once;
wherein density-dependent GC bias and/or nucleic acid damage in the amplification of the double-stranded DNA template is reduced.
US Pat. No. 10,391,117

METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON

Luitpold Pharmaceuticals,...

1. A method of treating a disease, disorder, or condition characterized by iron deficiency or dysfunctional iron metabolism resulting in reduced bioavailability of dietary iron, comprising administering to a subject in need thereof an iron carbohydrate complex in a single dosage unit of at least 0.7 grams of elemental iron, wherein:the iron carbohydrate complex is substantially non-immunogenic, and has substantially no cross reactivity with anti-dextran antibodies; and
the iron carbohydrate complex is an iron polyisomaltose complex.
US Pat. No. 10,392,656

COMPOSITIONS AND METHODS FOR DETECTION OF HEPATITIS A VIRUS NUCLEIC ACID

GEN-PROBE INCORPORATED, ...

1. A combination of at least two oligomers for amplifying a HAV target region comprising:for a second HAV target region,
a first amplification oligomer selected from (i) a promoter primer oligomer that includes a HAV target-specific portion of 21 to 27 contiguous nt contained in the sequence of SEQ ID NO:60, or (ii) a promoter primer oligomer in a size range of 48 to 54 at that includes a HAV target-specific portion of any one SEQ ID NOS:29 to 32; and
a second amplification oligomer of contiguous nt contained in the sequence of SEQ ID NO:86 that includes at least the sequence of SEQ ID NO:156.
US Pat. No. 10,396,240

III-NITRIDE SEMICONDUCTOR LIGHT EMITTING DEVICE HAVING AMBER-TO-RED LIGHT EMISSION (>600 NM) AND A METHOD FOR MAKING SAME

Ostendo Technologies, Inc...

10. A method of forming a III-nitride semiconductor LED comprising:forming over a substrate an active region having a plurality of sets of multiple quantum wells by;
forming over the substrate, the first set of multiple quantum wells having an indium concentration;
forming at least two additional sets of multiple quantum wells over the first set of multiple quantum wells, the formation of each additional set of multiple quantum wells being preceded by the formation of an AlxGa1-xN (0 the at least two additional set of multiple quantum wells having a higher indium concentration than the first set of multiple quantum wells; and
the first AlxGa1-xN (0
US Pat. No. 10,392,657

METHOD AND KIT FOR DETERMINING THE GENOME INTEGRITY AND/OR THE QUALITY OF A LIBRARY OF DNA SEQUENCES OBTAINED BY DETERMINISTIC RESTRICTION SITE WHOLE GENOME AMPLIFICATION

Menarini Silicon Biosyste...

1. A method for determining the integrity of the genome of a sample to be analysed by whole genome amplification (WGA) and/or the quality of a library of DNA sequences obtained by deterministic restriction site whole genome amplification (DRS-WGA) of the genome of the sample comprising the steps of:(a) providing a sample having a genome
(b) obtaining a library of DNA sequences by deterministic restriction site whole genome amplification (DRS-WGA) of the genome of the sample;
(c) amplifying the library of DNA sequences by PCR using:
at least one first primer pair which hybridizes to a DNA sequence of the library having a length from 1000 bp to 5000 bp and encompassing the D5S2117 region of chromosome 5q,
at least one second primer pair which hybridizes to a DNA sequence of the library having a length from 1000 bp to 5000 bp and encompassing exons 2 and 3 of the TRP53 gene of the genome, and
at least one third primer pair which hybridizes to a DNA sequence of the library having a length from 1000 bp to 5000 bp and encompassing the KRT19 pseudo-gene 1 of the genome,
wherein the step of amplifying giving rise to a first PCR product from 50 bp to 1000 bp, a second PCR product from 50 bp to 1000 bp having a size other than the first PCR product, and a third PCR product from 50 bp to 1000 bp having a size other than the first and second PCR products; and
(d) detecting the first, second and third PCR products,
wherein the presence of one or more of the first, second and third PCR products corresponds to a level of the integrity of the genome of the sample and/or the quality of the library of DNA sequences.
US Pat. No. 10,391,121

MAGNESIUM CHLORIDE COMPOSITION FOR DERMATOLOGICAL USE

BioPharmX, Inc., San Jos...

1. A topical composition, comprising:a magnesium salt dissolved in an anhydrous solvent comprised of a monohydric aliphatic alcohol and a polyol, wherein the composition does not comprise an active pharmaceutical ingredient other than the magnesium salt, wherein the monohydric aliphatic alcohol and polyol comprise 50-99.9% of the weight of the composition, and wherein the monohydric aliphatic alcohol and the polyol are in a ratio of from about 1:1 to 99:1.
US Pat. No. 10,392,660

ALTERNATIVE NUCLEOTIDE FLOWS IN SEQUENCING-BY-SYNTHESIS METHODS

LIFE TECHNOLOGIES CORPORA...

1. A method for sequencing a template polynucleotide strand comprising:(a) disposing a plurality of template polynucleotide strands into a plurality of reaction chambers, such that each reaction chamber has a template polynucleotide strand of the plurality having a sequencing primer hybridized thereto and a polymerase operably bound thereto;
(b) introducing a known nucleoside triphosphate into each reaction chamber according to a predetermined ordering of dNTP reagent flows;
(c) detecting sequential incorporation at the 3? end of the sequencing primer of one or more nucleoside triphosphates if the known nucleoside triphosphate is complementary to corresponding nucleotides in the template polynucleotide strands;
(d) washing away unincorporated nucleoside triphosphates from the reaction chamber; and
(e) repeating steps (b) through (d) until a desired template length of the plurality of template polynucleotide strands is sequenced;
wherein the predetermined ordering of dNTP reagent flows comprises an alternate ordering which is not a continuous and ordered repeat of four different dNTP reagent flows, the alternate ordering comprising a same number of flows for each of four different dNTP reagent flows, and at least one flow of each kind of dNTP reagent followed by a flow of the same kind of dNTP reagent after a single intervening flow of a different kind of dNTP reagent, and wherein repetition of the alternate ordering successively occurs at least once to sequence the desired template length.
US Pat. No. 10,391,122

NON-PYROGENIC PREPARATION COMPRISING NANOPARTICLES SYNTHESIZED BY MAGNETOTACTIC BACTERIA FOR MEDICAL OR COSMETIC APPLICATIONS

NANOBACTERIE, Paris (FR)...

1. A preparation comprising at least one synthetic nanoparticle, the at least one synthetic nanoparticle comprising:a crystallized mineral central part comprising predominantly an iron oxide, the central part having been produced by a living organism, and
a coating comprising materials not produced by said living organism, the coating covering the central part completely or partly,
wherein the coating does not comprise proteins produced by said living organism, and
wherein the least one synthetic nanoparticle comprises less than 12% in mass of carbon produced by said living organism.
US Pat. No. 10,392,661

DIGITAL COUNTING OF INDIVIDUAL MOLECULES BY STOCHASTIC ATTACHMENT OF DIVERSE LABELS

BECTON, DICKINSON AND COM...

1. A method, comprising:(a) attaching to one or more occurrences of a first target molecule and a second target molecule in a sample (i) a first label sequence randomly selected from a first set of label sequences and (ii) a second label sequence randomly selected from a second set of label sequences, thereby generating for each occurrence of the first target molecule and the second target molecule a new first molecule and a new second molecule, respectively,
wherein each new first molecule and new second molecule comprises a copy of the first target molecule and a copy of the second target molecule, respectively, and a combination label sequence comprising a first label sequence and a second label sequence,
wherein n1 and n2 are the numbers of the one or more occurrences of the first target molecule and the second target molecule, respectively, in the sample,
wherein combinations of each of the first set of label sequences and each of the second set of label sequences comprises m different combination label sequences, and
wherein the ratio of the greater of n1 and n2 to m is smaller than 0.2; and
(b) detecting the new first molecules and the new second molecules by detecting the combination label sequences present on the new first molecules and the new second molecules, wherein the detected new first molecules and the detected new second molecules indicate the number of the one or more occurrences of the first target molecule and the number of the one or more occurrences of the second target molecule, respectively.
US Pat. No. 10,391,123

ANTICANCER NANO-SILVER COMPOSITION FOR TREATMENT AND PREVENTION OF CERVICAL CANCER, AND PREPARATION METHOD AND USE THEREOF

1. A method of treatment of cervical cancer, comprising: administering to a patient in need thereof a therapeutically effective amount of an anticancer nano-silver composition;wherein the anticancer nano-silver composition comprises on a basis of per kilogram of total weight:
nano-silver powder 3-200 mg;
carbomer 700-1000 mg;
triethanolamine 700-1000 mg;
glucose 2.8-3.2 g;
water as remaining;
wherein, purity of silver of the nano-silver powder is ?99.99%, and particles of the nano-silver powder are 1-5 nm in size;
wherein, the anticancer nano-silver composition is prepared by a method which comprises:
(1) preparing the nano-silver powder, carbomer, triethanolamine, glucose and water in a ratio defined above;
(2) adding the carbomer into ½ to ? of total amount of the water with mixing; adding the nano-silver powder and the triethanolamine with mixing to obtain a mixture, which is then dispersed in a ultrasonic disperser for 2-5 min, wherein the ultrasonic disperser used in this step is of band 2 frequency: 16-24 KHz;
(3) adding the glucose and remaining water into the mixture dispersed in step (2) to obtain a mixture, which is then dispersed in a ultrasonic disperser for 1-3 min, wherein the ultrasonic disperser used in this step is of band 5 frequency: 40-65 KHz; and
(4) cooling the mixture dispersed in step (3) to 2-12° C. to obtain a mixture, which is dispersed in an ultrasonic atomizer into a mist, which is collected in a collecting device and is condensed to form an anticancer nano-silver solution, wherein the ultrasonic atomizer used in this step is of band 15 frequency: 120-180 KHz.
US Pat. No. 10,391,124

SILVER OXIDE FORMULATIONS

1. A method comprising:(a) providing a silver oxide raw material, said silver oxide raw material predominately including silver (II) oxide;
(b) milling said silver oxide raw material in a vortex mill, to produce a silver oxide powder in which the average particle size is smaller than an average particle size of said silver oxide raw material by at least one micrometer, and wherein said silver oxide powder has an average particle size (D50) within a range of from above 0.8 micrometers to below 8 micrometers;
wherein said silver oxide powder contains a silver (I) oxide and said silver (II) oxide, and wherein a concentration of said silver (I) oxide in said silver oxide powder exceeds a concentration of said silver (I) oxide in said silver oxide raw material.
US Pat. No. 10,392,663

HIGHLY-MULTIPLEXED SIMULTANEOUS DETECTION OF NUCLEIC ACIDS ENCODING PAIRED ADAPTIVE IMMUNE RECEPTOR HETERODIMERS FROM A LARGE NUMBER OF SAMPLES

ADAPTIVE BIOTECHNOLOGIES ...

1. A method for assigning a pair of first and second polypeptides that form a T-cell receptor (TCR) or Immunoglobulin (Ig) heterodimer to a single source sample among a plurality of source samples, comprising:(1) obtaining a plurality of source samples each comprising T-cells or B-cells;
(2) for each of the plurality of source samples, determining first rearranged nucleic acid sequences encoding first polypeptides of the TCR or Ig heterodimers present in the source sample and assigning the first rearranged nucleic acid sequences to the source sample;
(3) pooling the plurality of source samples to form a combined population of cells;
(4) determining from the combined population of cells, a plurality of cognate pairs of first and second rearranged nucleic acid sequences encoding first and second polypeptides of the TCR or Ig heterodimers;
(5) comparing the first rearranged nucleic acid sequences determined in each of the source samples in (2) to the first rearranged nucleic acid sequences determined from the plurality of cognate pairs of rearranged nucleic acid sequences in (4) to assign each first rearranged nucleic acid sequence present in the combined population to a single source sample; and
(6) for each first rearranged nucleic acid sequence assigned to a single source sample in step (5), assigning the cognate second rearranged nucleic acid sequence of the cognate pair identified in step (4) to the same single source sample.
US Pat. No. 10,392,664

SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBER

Natera, Inc., San Carlos...

1. A method of detecting aneuploidy of one or more chromosomes of interest in a fetus, the method comprising:obtaining fetal and maternal chromosome segments from cell-free DNA in a maternal blood sample comprising chromosome segments from the one or more chromosomes of interest and chromosome segments from one or more reference chromosomes;
ligating at least one adapter comprising a universal amplification sequence to the chromosome segments to obtain adapter-ligated chromosome segments;
performing universal amplification of the adapter-ligated chromosome segments to generate amplified chromosome segments;
measuring the amounts of the amplified chromosome segments; and
detecting aneuploidy of the one or more chromosomes of interest using the amounts of amplified chromosome segments from the one or more chromosomes of interest and the amounts of amplified chromosome segments from the one or more reference chromosomes.
US Pat. No. 10,391,126

CAR+ T CELLS GENETICALLY MODIFIED TO ELIMINATE EXPRESSION OF T-CELL RECEPTOR AND/OR HLA

BOARD OF REGENTS, THE UNI...

1. An engineered T cell population wherein cells of the population comprisea zinc finger nuclease that binds an endogenous HLA-A coding sequence,
a zinc finger nuclease that binds an endogenous T cell receptor (TCR) ? chain coding sequence, and
a nucleic acid sequence encoding a recombinant chimeric antigen receptor (CAR) comprising an intracellular signaling domain, a transmembrane domain and an extracellular domain comprising an antigen binding region, and
wherein the zinc finger nucleases induce simultaneous deletion in said HLA-A coding sequence and in said TCR ? coding sequence such that said cells of the population do not express the endogenous T cell receptor ? chain and do not express the endogenous HLA-A coding sequence.
US Pat. No. 10,392,665

BIOMARKER PAIRS FOR PREDICTING PRETERM BIRTH

Sera Prognostics, Inc., ...

1. A method of detecting a pair of isolated biomarkers consisting of IBP4/SHBG in a pregnant female, said method comprising:a. obtaining a biological sample from the pregnant female;
b. detecting whether the pair of isolated biomarkers is present in the biological sample by contacting the biological sample with a first capture agent that specifically binds a first member of said pair and a second capture agent that specifically binds a second member of said pair; and
c. detecting binding between the first biomarker of said pair and the first capture agent and between the second member of said pair and the second capture agent.
US Pat. No. 10,391,127

MESENCHYMAL STEM CELLS AND USES THEREFOR

1. A method of limiting inflammation in the gut in a patient suffering from inflammatory bowel disease, the method comprising the step of intravenously or intraarterially administering to the patient a suspension of isolated, cultured, genetically unmanipulated mesenchymal stem cells in an amount effective to limit inflammation in the gut.
US Pat. No. 10,392,409

FUNCTIONALIZED F-POSS MATERIALS AS ADDITIVES TO POLYMERS

NBD NANOTECHNOLOGIES, INC...

1. A method for synthesizing a functionalized F-POSS comprising:a) mixing a fluorinated alkylsilane (FAS) and at least one functionalized silane at a mole ratio of either 7:1, 6:2, 5:3, 4:4, 3:5, 2:6, or 1:7;
b) adding the mixture of step a) into a solvent;
c) adding an aqueous KOH solution as a catalyst to the solvent;
d) stirring the above at room temperature; and,
e) collecting precipitated final product.
US Pat. No. 10,392,667

METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY OF FULVESTRANT IN CANCER PATIENTS

1. A method of predicting the responsiveness of breast cancer in a patient to treatment with fulvestrant comprising:a) contacting a tumor sample from the patient comprising one or more nucleic acid molecules with a device comprising:
i) single-stranded nucleic acid molecules capable of specifically hybridizing with nucleotides of a GATA3 biomarker; and
ii) single-stranded nucleic acid molecules capable of specifically hybridizing with nucleotides of an ANXA1 biomarker; and
b) quantifying a level of expression of the GATA3 biomarker and the ANXA1 biomarker by performing microarray analysis, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), or qRT-loop-mediated isothermal amplification (LAMP),
c) predicting the cancer in the patient to be responsive to the treatment with fulvestrant if the level of expression of the GATA3 and ANXA1 biomarkers in the tumor sample is equal to or above a cutoff difference level of expression of the GATA3 and ANXA1 biomarkers in a cell or tissue known to be sensitive to the treatment with fulvestrant and predicting the cancer in the patient to be non-responsive to the treatment with fulvestrant if the level of expression of the GATA3 and ANXA1 biomarkers in the tumor sample is below the cutoff difference level of expression of the GATA3 and ANXA1 biomarkers in a cell or tissue known to be resistant to the treatment with fulvestrant, wherein the cutoff difference level is obtained by subtracting the level of the ANXA1 biomarker from the level of the GATA3 biomarker, and
(d) administering an effective amount of fulvestrant to said patient, wherein the patient has been determined to be responsive to fulvestrant.
US Pat. No. 10,391,129

MICROBIOTA RESTORATION THERAPY (MRT), COMPOSITIONS AND METHODS OF MANUFACTURE

REBIOTIX, INC., Rosevill...

1. A method for manufacturing a microbiota restoration therapy composition, the method comprising:collecting a plurality of fresh human fecal samples;
pooling the plurality of fresh human fecal samples;
adding a diluent to the pooled fresh human fecal samples to form a diluted sample;
wherein the diluent includes 30-90 g/L polyethylene glycol in saline;
mixing the diluted sample with a mixing apparatus;
filtering the diluted sample;
wherein filtering forms a filtrate;
transferring the filtrate to a sample bag; and
sealing the sample bag.
US Pat. No. 10,392,411

UNIVERSAL ENZYME RESPONSIVE LINKER FOR ASSEMBLING LIGANDS ON DNA FUNCTIONALIZED NANOMATERIALS

University of Connecticut...

1. A method of covalently linking two molecules comprising:(a) reacting a chemically-reactive moiety of a heterobifunctional linker with a first molecule comprising a functional group capable of covalently binding the chemically-reactive moiety of the heterobifunctional linker, wherein the heterobifunctional linker has the formula:
(HO)2(O)P—O—I—Y;whereinI is an intervening moiety, the intervening moiety having a molecular weight in the range of 100 to 10000; andY is a chemically-reactive moiety, the chemically-reactive moiety being reactable to couple the linker to an organic compound in aqueous solution, or a salt thereof, the chemically-reactive moiety and intervening moiety being selected such that the heterobifunctional linker, or salt thereof, is water soluble at a concentration of at least 10 pM at a pH within the range of 6.5 to 7.8;wherein the reacting occurs under conditions and for a time suitable to covalently bind the first compound to the chemically-reactive moiety of the heterobifunctional linker to form a first complex; and
(b) reacting the phosphate moiety of the heterobifunctional linker with a second molecule comprising a 3?-OH group of a nucleic acid phosphate in the presence of a T4 DNA ligase for a time and under conditions, to ligate the second molecule to the phosphate moiety of the first complex to form a phosphodiester bond between the nucleic acid phosphate and the phosphate moiety of the heterobifunctional linker.
US Pat. No. 10,392,668

EGFR ASSAY

ABBOTT MOLECULAR INC., D...

1. A composition for detecting EGFRvIII mRNA, the composition comprising a primer comprising a sequence according to SEQ ID NO: 1 or SEQ ID NO: 31, a primer comprising a sequence according to SEQ ID NO: 2, and a detectably labeled probe comprising a sequence according to SEQ ID NO: 3.
US Pat. No. 10,392,669

METHODS AND SYSTEMS FOR DETERMINATION OF AN EFFECTIVE THERAPEUTIC REGIMEN AND DRUG DISCOVERY

DNA-SEQ, Inc., La Jolla,...

1. A method for predicting the specificity profile of a therapeutic agent comprising:a) obtaining the crystal structure of the therapeutic agent;
b) identifying intermediate states of targets of the therapeutic agent; and
c) predicting the specificity profile of the therapeutic agent using the intermediate state of the target and a pattern matching algorithm with a crystal structure library,thereby predicting the specificity profile of a therapeutic agent.
US Pat. No. 10,391,131

THERAPEUTIC MICROBIOTA FOR THE TREATMENT AND/OR PREVENTION OF FOOD ALLERGY

1. A method, comprising administering to a subject having an inflammatory disorder a pharmaceutical composition comprising:a purified mixture of live bacteria for treatment of an inflammatory disorder in an individual in need thereof, wherein the live bacteria in the purified mixture consists of up to eleven bacterial species in total and includes the following bacterial species: Clostridium ramosum, Clostridium scindens, Clostridium hiranonis, Clostridium bifermentans, Clostridium leptum, and Clostridium sardiniensis; and
(ii) a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is formulated for intestinal delivery.
US Pat. No. 10,392,670

METHODS AND COMPOSITIONS FOR DETECTING BACTERIAL CONTAMINATION

DCH MOLECULAR DIAGNOSTICS...

1. A method of detecting bacterial contamination of a platelet sample by any of at least five bacterial genera, comprising:(a) subjecting the sample or a portion thereof to a nucleic acid amplification reaction under conditions to yield a detectable amount of an amplicon of no more than about 800 bases in a single reaction mixture, said reaction mixture comprising a single primer pair having a first primer and a second primer and a single detectable probe, wherein the first primer and the second primer each hybridizes to a separate conserved region of 16S rRNA polynucleotide, and the primer pair flanks the amplicon, wherein the amplicon comprises a conserved sequence to which the detectable probe hybridizes, and the conserved region is identical among the at least five bacterial genera,
wherein the conserved region is selected from the group consisting of from 9 to 28, from 32 to 48, from 888 to 903, from 908 to 937, from 975 to 994, from 957 to 981, from 1093 to 1125, from 1184 to 1206, from 1231 to 1252, from 1378 to 1396, from 1398 to 1422, or from 1496 to 1516, of 16S rRNA of Staphylococcus aureus (GenBank accession Number NC_007622) or the corresponding region in a genome of any one of the at least five bacterial genera; and
(b) detecting hybridization to the amplicon by the probe, wherein the hybridization by the probe yields a detectable signal indicative of bacterial contamination of the platelet sample by any of the at least five bacterial genera.
US Pat. No. 10,391,132

ONCOLYTIC VIRAL VECTORS AND USES THEREOF

ONCORUS, INC., Cambridge...

21. A method of treating a cancer in a subject in need thereof, comprising intratumorally administering a recombinant herpes simplex virus (HSV) to the subject, wherein the recombinant HSV comprises:a deletion in the internal repeat joint region such that the recombinant HSV genome comprises one copy of each of the ICP0, ?34.5, LAT, and ICP4 genes;
at least one copy of a micro-RNA (miR)-124 target sequence inserted into the ICP4 locus of the recombinant HSV genome and at least one copy of a miR-122 target sequence inserted into the ICP27 locus of the recombinant HSV genome;
thereby treating the cancer.
US Pat. No. 10,392,671

METHOD AND REAGENTS FOR DETECTING WATER CONTAMINATION

Dow Global Technologies L...

8. A method of examining a water supply for Legionella microbial contamination comprising:contacting a water supply sample with the reagent of claim 1; and
detecting or measuring the amount of binding between the reagent and target nucleic acids in the water supply sample to thereby detect or determine a contaminating concentration of a Legionella species in the water supply.
US Pat. No. 10,391,133

TRADITIONAL CHINESE MEDICINE COMBINATION FOR REGULATING IMMUNE FUNCTION AND PREPARATION METHOD THEREFOR

JIANGZHONG PHARMACEUTICAL...

1. A traditional Chinese medicine composition for regulating immunity, prepared with active ingredients and pharmaceutically acceptable carrier(s) and/or excipient(s), wherein the active ingredients consist of the following raw materials in parts by weight:i) 10 to 90 parts of Radix Panacis Quinquefolii and/or Radix Et Rhizoma Ginseng;
ii) 10 to 90 parts of Ganoderma;
iii) 5 to 50 parts of fermented Cordyceps sinensis powder and/or Cordyceps;
iv) 5 to 50 parts of Flos Rosae Rugosae;
v) 5 to 50 parts of Rhizoma Anemarrhenae;
vi) optionally, 10 to 50 parts of Bulbus Lilii; and
vii) optionally, 10 to 50 parts of Ganoderma spore powder and/or Ganoderma spore oil;
and/or extracts thereof.
US Pat. No. 10,392,672

YEAST STRAIN AND METHOD FOR PRODUCING NATURAL CINNAMIC ACID USING THE YEAST STRAIN FOR FERMENTATION

XIAMEN OAMIC BIOTECHNOLOG...

1. A method for producing natural cinnamic acid using the strain Rhodotorula sp. OMK-1 having preservation number CCTCC M 2015326, wherein the method comprises the steps of:1) strain activation;
2) seed culture; and
3) fermentation to produce natural cinnamic acid.
US Pat. No. 10,391,134

ANTI-CANDIDA COMPOSITIONS AND USES THEREOF

PHARMALP SA, Conthey (CH...

1. A method of treating a Candida albicans infection in a human in need thereof, the method comprising administering a therapeutically effective amount of an Epilobium parviflorum extract or a formulation of an Epilobium parviflorum extract to the human in need thereof to effectively treat the Candida albicans infection in the human in need thereof.
US Pat. No. 10,392,673

METHOD OF PRODUCING (-)-ROTUNDONE

T. HASEGAWA CO., LTD., T...

1. A method of producing (?)-rotundone from ?-guaiene, the method comprising the following steps (1) and/or (2):(1) allowing a cytochrome P450 protein to act on ?-guaiene, which cytochrome P450 (CYP) protein belongs to a CYP152 family and converts ?-guaiene to rotundone,
wherein the cytochrome P450 protein is SEQ ID NO:1, or a protein sequence having a sequence identity of at least 90% to the amino acid sequence of SEQ ID NO:1;
(2) allowing a cytochrome P450 protein to act on ?-guaiene in the presence of an electron transfer protein capable of transferring electrons to the cytochrome P450 protein, which cytochrome P450 (CYP) protein belongs to a CYP152, CYP106, or CYP107 family and converts ?-guaiene to rotundone,
wherein the cytochrome P450 protein is selected from the protein sequences of SEQ ID NOs:1 to 4, or a protein sequence having a sequence identity of at least 90% to an amino acid sequence of any of SEQ ID NOs:1 to 4.
US Pat. No. 10,391,135

INHIBITION OF FORMATION OF AMYLOID ?-PROTEIN FIBRILS USING CACTUS MUCILAGE EXTRACTS

University of South Flori...

1. A method of treating an amyloid disease, comprising the steps:identifying a patient suffering from an amyloid disease;
obtaining a plant mucilage extract, wherein the plant mucilage extract is gelling extract or non-gelling extract from Opuntia ficus-indica;
wherein the gelling extract is formed by steps comprising:
obtaining cactus pads;
dicing and boiling the cactus pads;
liquidizing the cactus pads and adding a base to neutralize the liquidized cactus pads;
centrifuging the liquidized cactus pads into a liquid fraction and a solid precipitate;
collecting the solid precipitate;
adding sodium hexametaphosphate to the solid precipitate and mixing;
filtering the solid precipitate;
resuspending the solid precipitate in deionized water to form a suspension;
lowering the pH of the suspension;
precipitating a mucilage precipitate from the suspension;
resuspending the mucilage precipitate with water and adjusting the pH until the mucilage precipitate dissolves; and
filtering the dissolved mucilage precipitate to form the gelling extract;
wherein the non-gelling extract is formed by steps comprising:
obtaining cactus pads;
dicing and boiling the cactus pads;
liquidizing the cactus pads and adding a base to neutralize the liquidized cactus pads;
centrifuging the liquidized cactus pads into a liquid fraction and a solid precipitate;
collecting the liquid fraction;
adding sodium chloride to the liquid fraction and mixing;
filtering the liquid fraction to form a filtrate;
adding acetone or isopropanol to the filtrate to form a mucilage precipitate;
washing the precipitate; and
drying the precipitate to form the non-gelling extract; and
administering the plant mucilage extract to the patient.
US Pat. No. 10,392,417

POLYMORPH OF REGADENOSON AND PROCESS FOR PREPARATION THEREOF

Apicore US LLC, Somerset...

1. A process for the preparation of stable polymorphic form C of regadenoson, comprising the steps of:a) obtaining a solution of Regadenoson in benzyl alcohol solvent;
b) maintaining the reaction mixture of step a) to about 10° C. to about 90° C.; and
c) isolating the stable polymorphic form C of regadenoson.
US Pat. No. 10,391,137

PLATELET-DERIVED GROWTH FACTOR-BB PRODUCTION PROMOTOR, AND MESENCHYMAL STEM CELL PRODUCTION ACCELERATOR, STEM CELL STABILIZER AND DERMAL REGENERATOR COMPRISING THE SAME

Shiseido Company, Ltd., ...

1. A method for promoting production of mesenchymal stem cells, comprising administering to a subject in need thereof an effective amount of a composition comprising a PDGF-BB production promoter as an active ingredient, wherein the effective amount is an amount sufficient to promote production of platelet-derived growth factor-BB (PDGF-BB), wherein the PDGF-BB production promoter is inositol or inositol phosphate, as the active ingredient, and wherein production of mesenchymal stem cells is increased.
US Pat. No. 10,391,138

MULTIDIMENSIONAL APPROACH FOR CANCER TREATMENT

Muniyal Ayurvedic Researc...

1. A method of treatment and management of Cancer, said method comprising: administering to a patient in need thereof a therapeutically effective amount of a herbo-mineral formulation and a bioactive formulation, wherein said herbo-mineral formulation comprisesWithania somnifera in an amount in the range of 6 to 10 wt. %,
Sida cordifolia in an amount in the range of 6 to 10 wt. %,
Asparagus racemosus in an amount in the range of 4 to 8 wt. %,
Tinospora cordifolia in an amount in the range of 4 to 8 wt. %,
Moringa oleifera in an amount in the range of 4 to 8 wt. %,
Picrorhiza kurroa in an amount in the range of 4 to 8 wt. %,
Ocimum sanctum in an amount in the range of 6 to 8 wt. %,
Curcuma longa in an amount in the range of 5 to 9 wt. %,
shilajit in an amount in the range of 4 to 8 wt. %,
Abhraka Bhasma in an amount in the range of 2 to 4 wt. %,
Trivanga Bhasma in an amount in the range of 0 to 2 wt. %,
Pravala Bhasma in an amount in the range of 0 to 2 wt. %,
Loha Bhasma in an amount in the range of 2 to 4 wt. % and
Swarna Makshika Bhasma in an amount in the range of 0 to 2 wt. %, of the total composition; and
said bioactive formulation comprises of processed Swarna bhasma and medicated honey.
US Pat. No. 10,392,420

GLYCOCONJUGATION PROCESS

Pfizer Inc., New York, N...

1. A method of making a glycoconjugate comprising a capsular polysaccharide from Group B Streptococcus (GBS) conjugated to a carrier protein, comprising the steps of:a) reacting said capsular polysaccharide with a stable nitroxyl radical compound and an oxidant wherein said oxidant is a molecule bearing a N-halo moiety which selectively oxidizes primary alcohols in the presence of a nitroxyl radical compound, to generate aldehyde groups to produce an activated capsular polysaccharide,
wherein said stable nitroxyl radical compound is a molecule bearing a TEMPO or a PROXYL (2,2,5,5-tetramethyl-1-pyrrolidinyloxy) moiety, having the ability to selectively oxidize primary alcohols in the presence of an oxidant, to generate aldehyde groups without affecting secondary hydroxyl groups; and
b) reacting the activated capsular polysaccharide with a carrier protein comprising one or more amine groups.
US Pat. No. 10,392,677

HIGH-STRENGTH HOT-PRESSED PART AND METHOD FOR MANUFACTURING THE SAME

JFE STEEL CORPORATION, T...

1. A high-strength hot-pressed part obtained by performing a hot pressing process on a steel sheet, the part having a chemical composition comprising, by mass %:C: 0.090% or more and less than 0.30%;
Mn: 3.5% or more and less than 11.0%;
Si: 0.01% to 2.5%;
P: 0.05% or less;
S: 0.05% or less;
Al: 0.005% to 0.1%;
N: 0.01% or less; and
the balance being Fe and inevitable impurities, the part having (i) a microstructure including, in terms of volume fraction, 80% or more of a martensite phase, in a range of 3.0% to 20.0% of a retained austenite phase, (ii) a tensile strength TS of 1500 MPa or more, and (iii) a uniform elongation uEl of 6.0% or more.
US Pat. No. 10,391,139

BLOOD PRESSURE REDUCTION WITH DIETARY SUPPLEMENTS

Biotics Research Corporat...

1. A dietary supplement composition for treating high blood pressure in a human in need thereof, said dietary supplement composition being formulated for oral ingestion and consisting essentially of therapeutically effective amounts of vitamin C, biotin, grapeseed extract, vitamin D3, Vitamin B6, taurine, and magnesium ascorbate.
US Pat. No. 10,391,140

PHARMACEUTICAL CYCLOSPORIN COMPOSITIONS

Sublimity Therapeutics Li...

1. An oral cyclosporin formulation comprising a solubilized cyclosporin, another active entity and at least one pharmaceutically acceptable excipient, wherein the cyclosporin is encapsulated with a gelling agent, and the composition is adapted to delay release of the cyclosporin and to release cyclosporin in the ileum and/or colon, wherein the formulation is selected from:a formulation comprising solid-, semi-solid or liquid filled seamless minicapsules comprising one or more layers, the minicapsules coated with a polymer composition providing a release profile to release the solubilized cyclosporin in the ileum and/or colon;ora formulation comprising minispheres coated with a polymer composition providing comprising (i) a hydrophobic solution comprising cyclosporin and (ii) gelatin in which the hydrophobic solution is encapsulated.
US Pat. No. 10,392,679

METHOD FOR RECOVERING GOLD FROM ACTIVATED CARBON

1. A method for eluting gold from an activated carbon on which at least sulfur (S) and gold (Au) are adsorbed, wherein the activated carbon is washed with an alkali solution to remove sulfur (S) before eluting the gold, and then the gold is eluted from the activated carbon.
US Pat. No. 10,392,423

PEPTIDE-BASED INHIBITORS OF MLL/SET1 FAMILY CORE COMPLEXES

The Research Foundation f...

1. A peptide that inhibits the formation of or disrupts MLL1 and SET1 complexes, wherein the peptide is 6-50 amino acid long and comprises the following sequence: ARX1X2X3X4 (SEQ ID NO:1), wherein X1 is A, S, L, V, W, Y, or T; X2 is E or Q; X3 is V, P, or G; and X4 is Y, K, or R, and wherein the N-terminus of the peptide is acetylated or the C-terminus is amidated.
US Pat. No. 10,392,680

COPPER ALLOY FOR ELECTRIC AND ELECTRONIC DEVICES, COPPER ALLOY SHEET FOR ELECTRIC AND ELECTRONIC DEVICES, COMPONENT FOR ELECTRIC AND ELECTRONIC DEVICES, TERMINAL, AND BUS BAR

MITSUBISHI MATERIALS CORP...

1. A copper alloy sheet for electric and electronic devices, wherein a composition of the copper alloy sheet consists of:0.01 mass % or higher and lower than 0.11 mass % of Zr;
0.002 mass % or higher and lower than 0.03 mass % of Si; and a balance including Cu and unavoidable impurities,
a ratio Zr/Si of a mass % of Zr to a mass % of Si is within a range of 2 to 30,
Cu—Zr—Si particles are dispersed in a matrix of copper, at least a part of the Cu—Zr—Si particles have a particle size of 1 nm to 500 nm, and
the copper alloy sheet has a surface Vickers hardness of 153 HV or higher.
US Pat. No. 10,391,143

MITOCHONDRIAL-DERIVED PEPTIDE MOTS3 REGULATES METABOLISM AND CELL SURVIVAL

THE REGENTS OF THE UNIVER...

1. A method of treating diabetes, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an isolated polypeptide or a pharmaceutically acceptable salt thereof comprising SEQ ID NO:1.
US Pat. No. 10,392,425

MULTIVALENT CD20-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS AND ENRICHED COMPOSITIONS THEREOF

Molecular Templates, Inc....

1. A cytotoxic composition comprising:a) a cytotoxic multivalent CD20-binding molecule, which multivalent CD20-binding molecule is multimeric and comprises or consists of at least two polypeptides linked by at least one covalent bond, each of said polypeptides having at least 98% sequence identity to an amino acid sequence selected from SEQ ID NO: 54 and SEQ ID NO: 55; wherein the cytotoxic multivalent CD20-binding molecule is capable of selectively killing a cell that expresses CD20 at a cellular surface; and
b) a monovalent CD20-binding molecule, wherein said monovalent CD20-binding molecule consists of a polypeptide having at least 98% sequence identity to an amino acid sequence selected from SEQ ID NO: 54 and SEQ ID NO: 55;wherein the ratio of the monovalent CD20-binding molecule concentration to the total CD20-binding molecule concentration is less than 1:5.
US Pat. No. 10,392,682

STEEL SHEET FOR THREE-PIECE CAN AND METHOD FOR MANUFACTURING THE SAME

JFE Steel Corporation, T...

1. A steel sheet for a three-piece can, the steel sheet having a chemical composition consisting of, by mass %, C: 0.0005% or more and 0.0035% or less, Si: 0.050% or less, Mn: 0.63% or more and 1.00% or less, P: 0.030% or less, S: 0.020% or less, Al: 0.010% or more and 0.100% or less, N: 0.0030% or less, B: 0.0005% or more, and the balance being Fe and inevitable impurities, wherein:the relationship B/N?0.50 is satisfied (where B/N represents (B(mass %)/10.81)/(N(mass %)/14.01));
a Young's modulus in a direction at an angle of 90° to a rolling direction is 220 GPa or more;
a Lankford value in the direction at the angle of 90° to the rolling direction is less than 1.00; and
an average ferrite grain size in the steel sheet is 10.0 ?m or less.
US Pat. No. 10,391,144

ATHEROSCLEROSIS INHIBITION VIA MODULATION OF MONOCYTE-MACROPHAGE PHENOTYPE USING APO A-I MILANO GENE TRANSFER

Cedars-Sinai Medical Cent...

1. A method of reducing plaque lipid content or plaque macrophage content in an aortic sinus, an innominate artery, or both, and optionally monitoring monocyte or macrophage phenotypic switching, in a subject in need of changing the phenotype of a monocyte or macrophage from a proinflammatory M1 phenotype to an anti-inflammatory M2 phenotype, comprising:administering to the subject an effective amount of a composition comprising serotype 8 recombinant adeno-associated virus (rAAV8) to change the phenotype of the monocyte or macrophage from the proinflammatory M1 phenotype to the anti-inflammatory M2 phenotype, said rAAV8 further comprises an exogenous gene encoding apolipoprotein A-I Milano (ApoA-I Milano),
wherein the plaque lipid content or the plaque macrophage content in the aortic sinus, the innominate artery, or both is reduced, and
wherein the serum level of ApoA-I Milano protein in the subject is 102 ng/mL or less at four weeks after administration of the rAAV8 by intravenous injection.
US Pat. No. 10,392,426

BLUE-LIGHT-ACTIVATED ION CHANNEL POLYPEPTIDES AND USES THEREOF

Massachusetts Institute o...

1. An isolated light-activated ion channel polypeptide; wherein the light-activated ion channel polypeptide is activated when contacted with blue light; and the light-activated ion channel polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 4, or a variant thereof comprising the amino acid sequence set forth as SEQ ID NO: 4 with one or more amino acid sequence modifications and with at least 90% amino acid identity to the corresponding sequence of SEQ ID NO: 4 with which it aligns.
US Pat. No. 10,392,683

RAIL VEHICLE AXLE

NIPPON STEEL CORPORATION,...

1. A rail vehicle axle comprising:a chemical composition consisting of, in mass %,
C: 0.20 to 0.35%,
Si: 0.20 to 0.65%,
Mn: 0.40 to 1.20%,
P: 0.020% or less,
S: 0.020% or less,
Cu: 0.01 to 0.30%,
Ni: 0 to 0.30%,
Cr: 0 to 0.30%,
Mo: 0.005 to 0.08%,
Al: 0 to 0.100%,
N: 0.0200% or less,
V: 0 to 0.060%, and
Ti: 0 to 0.020%, with the balance being Fe and impurities, and satisfying Formulae (1) and (2):
0.58?C+Si/8+Mn/5+Cu/10+Cr/4+V?0.67  (1)
Si+0.9Cr?0.60  (2)
where each element symbol in Formulae (1) and (2) is substituted by the content (mass %) of a corresponding element,
wherein the tensile strength is 590 to 650 MPa.
US Pat. No. 10,391,145

COMBINED USE OF A VECTOR ENCODING A MODIFIED RECEPTOR AND ITS EXOGENOUS AGONIST IN THE TREATMENT OF SEIZURES

UCL BUSINESS PLC, London...

1. A method of treating a seizure disorder, which is focal epilepsy, in a patient suffering from said disorder,wherein either
(a) said patient has previously been administered a vector encoding a modified receptor,
wherein the modified receptor is a human muscarinic acetylcholine receptor M4, which is a Gi protein-coupled receptor (GPCR), coupled via a Gi-protein to a G protein-coupled inwardly rectifying potassium channel (GIRK), and
wherein the modified receptor is characterised by (i) a decreased responsiveness to its endogenous activating ligand and/or (ii) a retained or enhanced responsiveness to an exogenous agonist, or
(b) administering to the patient said vector,
wherein the modified receptor is encoded by a nucleic acid operably linked to a neuronal cell type-specific promoter such that said modified receptor is expressed in excitatory neurons of a seizure focus in brain of the patient;
which method comprises subsequently administering to said patient an exogenous agonist selected from clozapine, clozapine-N-oxide and perlapine,whereby the presence of said agonist in the brain of the patient activates said modified receptor,whereby activation of said modified receptor reversibly inhibits the excitability of, and neurotransmission by, the excitatory neurons in the seizure focus.
US Pat. No. 10,392,427

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a patient who has lung cancer, comprising administering to said patient a population of activated T cells that selectively recognize cells that present a peptide consisting of the amino acid sequence of YPKDIYSSF (SEQ ID NO: 223).
US Pat. No. 10,392,684

METHOD FOR THE PRODUCTION OF AN ANODISED, TURNED MECHANICAL PART MADE FROM 6XXX ALLOY AND HAVING LOW ROUGHNESS AFTER ANODISATION

CONSTELLIUM EXTRUSION DEC...

1. Method for producing a mechanical part comprisinga. an aluminum alloy billet is cast having a composition in wt % of Si 0.4-3.0; Mg 0.6-2.0; Cu 0.20-1.0; Fe 0.15-1.8; Mn?0.5; Ni?1; Ti<0.15; Cr?0.35; Bi?0.8; Pb?0.4; Zr<0.04, other elements <0.05 each and <0.15 total, balance aluminum,
b. said billet is homogenized,
c. said billet is extruded to obtain an extruded product,
d. quenching is done while at extrusion heat,
e. artificial aging is performed,
f. the extruded product thus obtained is machined to make a turned mechanical part,
g. the resulting mechanical part is anodized, said anodization being performed at a temperature of between 15 and 40° C. with a solution consisting of 100 to 250 g/l sulfuric acid and 10 to 30 g/l oxalic acid, and 5 to 30 g/l of at least one polyhydric alcohol, and with a current density of between 1 and 5 A/dm2,
wherein the at least one polyhydric alcohol is selected from the group consisting of ethylene glycol, propylene glycol, and glycerol.
US Pat. No. 10,391,146

METHOD TO FUNCTIONALIZE CELLS IN HUMAN BLOOD, OTHER FLUIDS AND TISSUES USING NANOPARTICLES

Cornell University, Itha...

1. A method of killing metastatic cancer cells comprising:a) providing nanoparticles which are functionalized with antibodies to CD57 and therapeutic molecules selected from the group consisting of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and Fas ligand, wherein the antibodies to CD57 on the nanoparticles bind to CD57 on NK-1 cells in circulation, and wherein the TRAIL interacts with DR4 and DR5 receptors, and the Fas ligand interacts with Fas on cancer cells causing apoptosis of the cancer cells; and
b) introducing the nanoparticles into the circulation of an individual in need of treatment thereby allowing the nanoparticles to bind to the NK-1 cells and the NK-1 cells to seek out cancer cells thereby causing the nanoparticles to interact with the cancer cells via the therapeutic molecules causing cell death of the cancer cells.
US Pat. No. 10,395,757

PARENTAL GENOME ASSEMBLY METHOD

BGI TECH SOLUTIONS CO., L...

1. A method of obtaining genomes of parents, wherein the parents consist of parent A and parent B, and the method comprises steps:a) providing reads and scaffolds, comprising:
a1) subjecting the parents to a whole genome sequencing respectively, to provide the reads deriving from the parents, wherein the reads of the parent A constitute a database A0, the reads of the parent B constitute a database B0;
a2) connecting the reads in the database A0 into scaffolds of the parent A; and connecting the reads in the database B0 into scaffolds of the parent B, wherein the scaffolds of the parent A constitute a database A1, the scaffolds of the parent B constitute a database B1;
a3) providing inbred lines progeny population of the parents, wherein the inbred lines progeny population comprises at least one of inbred lines progeny individuals; and
a4) subjecting every inbred lines progeny individual to the whole genome sequencing respectively, to provide paired reads of every inbred lines progeny individual, wherein the paired reads constitute a database C, namely, reads of the inbred lines progeny population;
b) identifying a segregation site of the parents, comprising:
b1) when other genomes of a species to which the parents belong are known,
selecting a known genome as a reference sequence;
aligning the reads in the database A0 and the database B0 to the reference sequence respectively, to obtain consensus genotype sequences of the parent A and the parent B respectively;
comparing the consensus genotype sequences of the parent A and the parent B, to identify a different site presenting between the parents, namely, the segregation site;
determining a genotype of the parent A and parent B at the segregation site respectively; and
recording a position of the segregation site in the reference sequence; or
b2) when other genomes of a species to which the parents belong are unknown,
selecting and assembling the reads deriving from one of the parents into an initial genome sequence as a reference sequence;
aligning the reads deriving from the other one of the parents to the reference sequence, to obtain a consensus genotype sequence of the parents respectively;
comparing the consensus genotype sequences of the parent A and the parent B, to identify a different site presenting between the parents, namely, the segregation site;
determining a genotype of the parent A and the parent B at the segregation site respectively;
recording a position of the segregation site in the reference sequence;
c) obtaining genome drafts of the parents, comprising:
c1) selecting a sequence located 10 bp to 90 bp before and/or 10 bp to 90 bp after the segregation site in the consensus genotype sequences of the parent A and the parent B as a marker sequence of the parent A and the parent B respectively, and
recording a position of the marker sequence in the reference sequence in step b);
c2) locating the marker sequence of the parent A on the scaffolds in the database A1 and locating the marker sequence of the parent B on the scaffolds in the database B1 using a global alignment software, wherein the marker sequence should be uniquely and completely accurately aligned to the scaffolds located thereof; and
c3) based on the position of the marker sequence in the reference sequence, arranging the scaffolds comprising the marker sequence in the database A1 and the database B1 in order, wherein an unknown sequence between two neighboring scaffolds is represented as an N-region, to obtain the genome drafts of the parent A and the parent B;
d) classifying the reads in the database C, comprising:
d1) aligning the reads in the database C to the reference sequence in step b), to determine whether these reads comprise the segregation site recorded in the reference sequence, and to determine a genotype thereof at the segregation site;
d2) based on the respective genotype of the parent A and the parent B at the segregation site in step d1), classifying the reads in the database C into 3 categories:
i) reads of which the genotype at the segregation site is consistent with the genotype of the parent A, derives from the parent A, and constitute a database A2;
ii) reads of which the genotype at the segregation site is consistent with the genotype of the parent B, derives from the parent B, and constitute a database B2;
iii) undistinguishable reads; and
d3) connecting the reads in the database A2 into new scaffolds of the parent A, to constitute a database A3; connecting the reads in the database B2 into new scaffolds of the parent B, to constitute a database B3, and
e) obtaining the genome of the parent A and the parent B by following steps:
e1) improving the genome drafts of the parent A using the scaffolds in the database A3 and improving the genome drafts of the parent B using the scaffolds in the database B3, comprising:
e1-1) selecting a continuous sequence having a length of 50 bp to 150 bp within 200 bp to 400 bp of a non-N region sequence in the genome drafts of the parent A and the parent B as a signing sequence respectively, and recording a position of the signing sequence in the genome drafts;
e1-2) locating the signing sequence of the parent A on the scaffolds in the database A3, locating the signing sequence of the parent B on the scaffolds in the database B3, wherein the signing sequence should be uniquely and completely accurately aligned to the scaffolds located thereof; and
e1-3) based on the position of the signing sequence in the genome drafts,
locating the scaffolds comprising the signing sequence in the database A3 in the position of the signing sequence in the genome drafts of the parent A,
locating the scaffolds comprising the signing sequence in the database B3 in the position of the signing sequence in the genome drafts of the parent B, and
filing up the N region in the genome drafts using the scaffolds comprising the signing sequence; and/or
e2) improving the genome drafts of the parent A using a pairwise relationship between the reads in the database A2 and improving the genome drafts of the parent B using a pairwise relationship between the reads in the database B2, comprising:
e2-1) finding paired reads having the pairwise relationship in the database A2, wherein one of the paired reads is located in the non-N region in the genome draft of the parent A, while at least one part of the other one of the paired reads is located in the N region; then filling up the N region in the genome draft of the parent A using the other one of the paired reads; and
e2-2) finding paired reads having the pairwise relationship in the database B2, wherein one of the paired reads is located in the non-N region in the genome draft of the parent B, while at least one part of the other one of the paired reads is located in the N region; then filling up the N region in the genome draft of the parent B using the other one of the paired reads.
US Pat. No. 10,391,147

FUSION PROTEINS CONTAINING INSULIN-LIKE GROWTH FACTOR-1 AND EPIDERMAL GROWTH FACTOR AND VARIANTS THEREOF AND USES THEREOF

IGF Oncology, LLC, Pine ...

1. A fusion polypeptide consisting of (a) SEQ ID NO:1 or residues 2-18 of SEQ ID NO:1; fused directly to the N-terminus of (b) a protein.
US Pat. No. 10,392,429

BIPHASIC SINGLE-CHAIN INSULIN ANALOGUES

Case Western Reserve Univ...

1. A single-chain insulin comprising:a C-domain of from 6 to 11 amino acid residues comprising at least two acidic residues at the N-terminal side of the C-domain and at least two basic residues at the C-terminal side of the C-domain peptide, wherein the amino acids at the N-terminal side of the C-domain are the amino acids Glu-Glu;
a basic amino acid residue at the position corresponding to A8 of human insulin, and
an acidic amino acid residue at the position corresponding to A14 of human insulin.
US Pat. No. 10,391,148

METHOD OF PREVENTION AND INHIBITION OF PRETERM LABOR

Wayne State University, ...

1. A method of preventing and/or inhibiting preterm labor in a pregnant subject, comprising:administering a therapeutically effective amount of a protein selected from the group consisting of: PIBF1 protein comprising SEQ ID NO:1 or SEQ ID NO:2, a variant thereof that is at least 99% identical to SEQ ID NO: 1, wherein substitution mutations in the variant are conservative substitutions, a variant thereof that is at least 99% identical to SEQ ID NO: 2, wherein substitution mutations in the variant are conservative substitutions, a variant thereof that is encoded by the complement of a nucleic acid that hybridizes under highly stringent conditions with the nucleotide sequence of SEQ ID NO: 3, and a variant thereof that is encoded by the complement of a nucleic acid that hybridizes under highly stringent conditions with the nucleotide sequence of SEQ ID NO: 4, wherein the highly stringent conditions comprise hybridization in 6×SSC, 5×Denhardt's solution, 30% formamide, and 100 microgram/ml denatured salmon sperm at 37° C. overnight followed by washing in a solution of 0.1×SSC and 0.1% SDS at 60° C. for 15 minutes: IL-33, a fragment or variant thereof; and a combination of any two or more thereof, to a pregnant subject in need thereof.
US Pat. No. 10,392,430

METHODS OF MAKING NUCLEIC ACID MOLECULES ENCODING MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES

REGENERON PHARMACEUTICALS...

1. A method for making a nucleic acid molecule encoding a chimeric VEGF-binding fusion protein with improved pharmacokinetic properties, the method comprising: modifying a nucleic acid molecule encoding immunoglobulin (“Ig”) domains 1, 2 and 3 of Flt1 fused to an Fc domain (“Flt1(1-3)-Fc”), wherein said modifying comprises: (a) deleting the nucleotide sequence encoding the first Ig domain of Flt1; and (b) replacing the nucleotide sequence encoding the third Ig domain of Flt1 with the nucleotide sequence encoding the third Ig domain of Flk1 or Flt4;thereby making a nucleic acid molecule encoding a chimeric VEGF-binding fusion protein with reduced binding to extracellular matrix (ECM) and improved pharmacokinetics (PK) as compared to Flt1(1-3)-Fc.
US Pat. No. 10,395,759

METHODS AND SYSTEMS FOR COPY NUMBER VARIANT DETECTION

REGENERON PHARMACEUTICALS...

1. A method comprising:receiving, by a computing device, a sample coverage data set comprising a plurality of genomic sequences obtained from sequencing of nucleic acid samples of a subject, and sample sequencing quality control (SSQC) metrics;
grouping, by the computing device, sets of sequencing quality control (SQC) metrics into a multidimensional tree data structure according to similarity, wherein each set of SQC metrics is associated with a respective reference coverage data set that comprises a plurality of genomic regions and read depths;
selecting, by the computing device, a reference panel of reference coverage data sets using the multidimensional tree data structure, wherein the selected reference coverage data sets have SQC metrics similar to the SSQC metrics;
normalizing, by the computing device, the sample coverage data set and the reference panel;
fitting, by the computing device, the normalized reference panel to a mixture model at each of the plurality of genomic regions to determine an expected coverage distribution at each of the plurality of genomic regions; and
identifying one or more copy number variants (CNVs) by comparing, by the computing device, according to a Hidden Markov Model (HMM), the normalized sample coverage data set to the expected coverage distribution at each of the plurality of genomic regions from the mixture model.
US Pat. No. 10,391,149

METHODS TO ENHANCE NERVE REGENERATION UTILIZING NEURAL STEM CELLS AND IL12P40

NATIONAL HEALTH RESEARCH ...

1. A method for regenerating nerve, comprising administering a nerve conduit containing a nerve regeneration composition to a subject, wherein the nerve regeneration composition comprises a homodimer of interleukin-12 subunit p40 (IL12p40).
US Pat. No. 10,392,431

POLYNUCLEOTIDE ENCODING IL-35 RECEPTOR

1. An isolated polynucleotide or mixture of polynucleotides, comprising:(a) a first polynucleotide sequence encoding the extracellular domain of the polypeptide sequence set forth in SEQ ID NO:3, wherein the first polynucleotide is operably linked to a first heterologous regulatory sequence; and
(b) a second polynucleotide sequence encoding the extracellular domain of the polypeptide sequence set forth in SEQ ID NO:6, wherein the second polynucleotide is operably linked to a second heterologous regulatory sequence.
US Pat. No. 10,391,150

TREATMENTS FOR MIGRAINE AND RELATED DISORDERS

The Universit of Chicago,...

1. A method for treating a patient subject to seizures comprising administering to the patient an effective amount of a composition comprising insulin growth factor-1 (IGF-1), wherein treating excludes administering a cytokine to the patient.
US Pat. No. 10,392,432

HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ

REGENERON PHARMACEUTICALS...

1. An isolated antibody or antigen-binding fragment thereof, comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) comprising the amino acid sequence set forth in SEQ ID NO: 18; and three light chain complementarity determining regions (CDRs) (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) comprising the amino acid sequence set forth in SEQ ID NO: 26.
US Pat. No. 10,391,151

DILUTE SURFACTANT OR ISOLATED SURFACTANT PROTEIN SOLUTION FOR THE REDUCTION OF SURFACE TENSION IN THE LUNG

The Trustees of the Steve...

1. A method of reducing ventilation injury to a patient whose lung has regions with heterogeneous alveolar flooding by alveolar liquid, said method comprising the step of (i) delivering to the patient a solution comprising a predetermined amount of a surfactant protein C and a negatively charged solute, wherein said negatively charged solute is present in the alveolar liquid in a concentration which is in a range of from greater than 2 weight/volume percent to less than 12 weight/volume percent after the performance of step (i) and wherein said predetermined amount of said surfactant protein C is selected to provide a concentration of said surfactant protein C in the alveolar liquid in a range of from 0.000001 weight/volume percent to 1 weight/volume percent, said weight/volume percent of said surfactant protein C and said negatively charged solute being based on the total volume of the alveolar liquid after the performance of step (i).
US Pat. No. 10,392,690

METHOD FOR SYNTHESIZING A THIN FILM STAINLESS STEEL COATING

Kuwait Institute for Scie...

1. A method for synthesizing a thin film stainless steel coating, comprising:using electron-beam PVD coating to provide a thin film stainless steel coating on a target surface, the electron-beam PVD coating comprising conducting thermal evaporation of a source stainless steel material at a percentage of electron beam power ranging from about 3% to about 4% and a vacuum pressure of 6×10?6 Torr, wherein the source stainless steel material comprises a plurality of stainless steel balls, further wherein the source stainless steel material has a first grade and the thin film stainless steel coating has a second grade that is different from the first grade, wherein the second grade includes predetermined percentages of Fe, Ni, Mn, Mo, and Cr; and
the thin film stainless steel coating has a uniform thickness of from 1 nm to 150 nm distributed uniformly on the target surface.
US Pat. No. 10,391,152

METHODS OF USING A FIXED DOSE OF A CLOTTING FACTOR

Bioverativ Therapeutics I...

1. A method of treating hemophilia B in a subject in need thereof, comprising administering a fixed dose of chimeric Factor IX (FIX) polypeptide to the subject,wherein the fixed dose is standard across all body weight,
wherein the fixed dose is administered weekly at a dose between about 3,000 IU and about 4,000 IU, and
wherein the chimeric FIX polypeptide comprises:
(i) a first polypeptide chain comprising a FIX-Fc amino acid sequence having at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence according to SEQ ID NO: 2, and
(ii) a second polypeptide chain comprising an Fc amino acid sequence having at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity sequence identity to the amino acid sequence according to SEQ ID NO: 4.
US Pat. No. 10,392,434

TREATING REFRACTORY MIGRAINE

Teva Pharmaceuticals Inte...

1. A method of treating migraine in a subject, the method comprising:selecting a subject who has an inadequate response to two or more different classes of preventative migraine treatment selected from the group consisting of beta-blockers, anticonvulsants, tricyclics, calcium channel blockers, angiotensin II receptor antagonists, onabotulinumtoxinA, and valproates; and
administering to the subject a therapeutically effective amount of a humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody comprising the amino acid sequence of the heavy chain variable region set forth in SEQ ID NO: 1 and the amino acid sequence of the light chain variable region set forth in SEQ ID NO: 2.
US Pat. No. 10,393,203

ACRYLIC RUBBER COMPOSITION

NOK Corporation, Tokyo (...

1. An acrylic rubber composition comprising 20 to 80 parts by weight of a functional group-containing styrene acrylic-based resin containing a hydroxyl group or an epoxy group as the functional group, and 0.1 to 5 parts by weight of sulfur or a sulfur-containing vulcanization accelerator, based on 100 parts by weight of acrylic rubber.
US Pat. No. 10,391,153

METABOLIC THERAPY FOR OXIDATIVE STRESS IN THE BRAIN THROUGH TARGETED NEURONAL CATABOLISM OF N-ACETYL-ASPARTIC ACID

Rowan University, Glassb...

13. A gene delivery construct comprising a vector and a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1.
US Pat. No. 10,392,435

METHOD FOR DECREASING DEPRESSION-LIKE BEHAVIOR WITH CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITOR

The Board of Trustees of ...

1. A method for decreasing depression-like behavior in an individual in need thereof, the method comprising:(a) administering to the individual a therapeutically effective amount of a connective tissue growth factor (CTGF) inhibitor.
US Pat. No. 10,391,154

COMPOSITIONS AND METHODS FOR TREATING OR AMELIORATING FIBROSIS, SYSTEMIC SCLEROSIS AND SCLERODERMA

LEADIANT BIOSCIENCES LTD....

1. A method for arresting, treating, ameliorating or preventing scleroderma-associated vasculopathies and vascular changes, or preventing or decreasing progression of scleroderma in an individual in need thereof, comprising:(a) (i) providing or having provided an Adenosine Deaminase (ADA) enzyme or a composition comprising an Adenosine Deaminase (ADA) enzyme; and
(ii) administering or having administered an effective amount of the ADA enzyme or composition to the individual in need thereof; or
(b) administering an effective amount of an Adenosine Deaminase (ADA) enzyme or a composition comprising an Adenosine Deaminase (ADA) enzyme to the individual in need thereof.
US Pat. No. 10,392,436

ANTI-HUMAN IL-17 MONOCLONAL ANTIBODIES AND USE THEREOF

BEIJING BETTERMAB BIOTECH...

1. A monoclonal antibody that specifically binds to human IL-17A, comprising a heavy chain variable region comprising HCDR1, HCDR2 and HCDR3 and a light chain variable region comprising LCDR1, LCDR2 and LCDR3;wherein HCDR1 has the sequence GX1X2X3X4X5Y, HCDR2 has the sequence NQDGX6E (SEQ ID NO: 35), and HCDR3 has the sequence DYYDX7ISDYYIHYWYFDL (SEQ ID NO: 36), wherein the sequence X1X2X3X4X5 is FTIDN (SEQ ID NO: 37), MSMSD (SEQ ID NO: 38) or ITMDD (SEQ ID NO: 39), X6 is N or D, X7 is V or L;
wherein LCDR1 has the sequence RASQNVHNRLT (SEQ ID NO: 40), LCDR2 has the sequence GASNLES (SEQ ID NO: 41), and LCDR3 has the sequence QQYNGSPTT (SEQ ID NO: 42); and
wherein HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined according to Chothia.
US Pat. No. 10,391,155

PEPTIDIC CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF

THE SCRIPPS RESEARCH INST...

1. A method of treating a cancer in a subject comprising:a. administering to the subject a first chimeric antigen receptor-effector cell (CAR-EC) switch, wherein the first CAR-EC switch comprises:
i. a first peptidic antigen comprising a yeast transcription factor GCN4 peptide that binds to and activates a chimeric antigen receptor on an effector cell; said GCN4 peptide comprising a portion of SEQ ID NO:2 that is at least 12 amino acids; and
ii. a first targeting moiety that binds a cell surface molecule on a target cell; wherein the first targeting moiety comprises an antibody, or an antigen binding fragment of an antibody;
wherein the first peptidic antigen is grafted or fused to the first targeting moiety, and
b. administering to the subject a first chimeric antigen receptor-effector cell comprising an anti-GCN4 chimeric antigen receptor that binds to the first peptidic antigen of the first chimeric antigen receptor-effector cell switch;
wherein the effector cell is a T cell.
US Pat. No. 10,392,437

ERYTHROCYTE-BINDING THERAPEUTICS

1. A composition for use in inducing tolerance comprising:an antigen to which tolerance is desired;
wherein the antigen is selected from the group consisting of insulinoma-associated protein 2 (IA-2) and an immunogenic portion of said IA-2;
an erythrocyte-binding moiety,
wherein the erythrocyte-binding moiety comprises an antibody fragment that has the ability to non-covalently, specifically bind an exterior erythrocyte surface in situ in blood,
wherein the erythrocyte-binding moiety is affinity matured,
wherein the antigen to which tolerance is desired is recombinantly fused to the erythrocyte-binding moiety,
wherein, upon administration to a human in which tolerance to the antigen is desired:
the composition binds to CD45 negative cells, but not to CD45 positive cells, and the composition reduces, fails to induce, or prevents inflammatory responses in antigen-specific T cells as compared to when the human is exposed to the antigen alone, and
wherein the composition reduces the number of resident lymph node and spleen cells expressing interferon-gamma (IFN?), as compared to the number of resident lymph node and spleen cells expressing IFN? when the human is exposed to the antigen alone.
US Pat. No. 10,391,156

UNIVERSITY DONOR CELLS AND RELATED METHODS

ViaCyte, Inc., San Diego...

1. A human in vitro pancreatic cell population comprising CHGA?, NKX6.1+, PDX1+ pancreatic progenitor cells, and CHGA+ pancreatic endocrine cells,wherein the function of at least one major histocompatibility complex (MHC)-Class I gene and at least one Natural killer (NK) cell activating ligand is disrupted or inhibited, resulting in reduced binding of the NK activating ligand to a NK activating receptor in the human in vitro pancreatic cell population.
US Pat. No. 10,391,669

METHOD FOR THE PRODUCTION OF LIGNOCELLULOSE MATERIALS

BASF SE, Ludwigshafen am...

1. A process for the production of isocyanate-bound lignocellulose materials, the process comprising:mixing:
A) lignocellulose-containing particles or fibers,
B) organic isocyanate having at least two isocyanate groups or a mixture of these,
C) optionally binders selected from the group of the phenol-formaldehyde resins, the aminoplastic resins, the protein-based binders, and other polymer-based binders, and mixtures of these,
D) optionally additives or a mixture of these, and
E) optionally plastics particles or a mixture of these,
to form a mixture
i.) scattering the resultant mixture to give a mat,
ii.) precompacting and heating the mat during or after the precompaction process, and
iii.) hot pressing,
wherein, in the step ii.), operations are carried out at elevated temperature of from 55 to 90° C. during and/or after the precompaction process, the mat, at the juncture at which the final heating temperature is reached in the center of the mat, the mat has a height of from 27.5 to 60% of the height of the mat immediately after the scattering of the mat, and a push-off value of at least 4 cm.
US Pat. No. 10,392,438

BISPECIFIC ANTIBODIES

PFIZER INC., New York, N...

1. A heterodimeric protein, comprising(i) a first CH1 domain (CH1) and a first CL domain (CL), the first CH1 and the first CL interacting together at a first CHCL interface to form a first CHCL domain (CHCL);
(ii) a second CH1 domain (CH1) and a second CL domain (CL), the second CH1 and the second CL interacting together at a second CHCL interface to form a second CHCL domain (CHCL);
wherein the first CH1 is engineered to differ from the second CH1 by at least one CH1 mutant residue in the first CH1; and
wherein the first CL is engineered to differ from the second CL by at least one CL mutant residue in the first CL;
such that the at least one CH1 mutant residue in the first CH1 and the at least one CL mutant residue in the first CL interact with each other in preference to the corresponding at least one CH1 mutant residue in the second CH1 and at least one CL mutant residue in the second CL;
wherein the interacting mutant residues of the first CH1 and first CL thereby form a first complementary residue set;
wherein the location of the first complementary residue set is selected from the group consisting of:
(i) Ch1-124 and CL-176;
(ii) CH1-221 and CL-123;
(iii) CH1-186 and CL-131; and
(iv) CH1-122 and CL123;
and wherein the first CH1 is attached to a first variable heavy domain (VH), and the first CL is attached to a first variable light domain (VL), and the second CH1 is attached to a second VH, and the second CL is attached to a second VL, such that when combined, the first VH, first VL, first CH1 and first CL together form a first Fab, and when combined, the second VH, second VL, second CH1, and second CL form a second Fab,
and wherein preferential formation of the first Fab and the second Fab does not rely on complementary pairing of the variable domains.
US Pat. No. 10,391,157

MATERIALS AND METHODS FOR PRODUCING IMPROVED LENTIVIRAL VECTOR PARTICLES

IMMUNE DESIGN CORP., Sea...

1. A method of generating a pseudotyped lentiviral vector particle comprising:(a) culturing in a culture medium comprising kifunensine a virus packaging cell comprising:
(1) a lentiviral vector genome comprising an exogenous polynucleotide of interest,
(2) a polynucleotide encoding a Sindbis E2 glycoprotein that preferentially binds dendritic cells expressing DC-SIGN, and
(3) a polynucleotide encoding a Vpx protein or a Vpr protein that retains SAMHD1-inhibiting activity; and
(b) isolating a pseudotyped lentiviral vector particle that preferentially binds dendritic cells expressing DC-SIGN.
US Pat. No. 10,392,439

METHODS FOR TREATING ALLERGY AND ENHANCING ALLERGEN-SPECIFIC IMMUNOTHERAPY BY ADMINISTERING AN IL-4R INHIBITOR

Regeneron Pharmaceuticals...

1. A method for treating or reducing the severity of an allergic reaction, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist to a subject in need thereof, wherein the IL-4R antagonist is an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDRs) (HCDR1, HCDR2 and HCDR3) and three light chain complementarity determining regions (LCDRs) (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3; the HCDR2 comprises the amino acid sequence of SEQ ID NO:4; the HCDR3 comprises the amino acid sequence of SEQ ID NO:5; the LCDR1 comprises the amino acid sequence of SEQ ID NO:6; the LCDR2 comprises the amino acid sequence of SEQ ID NO:7; and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8, wherein the allergic reaction is triggered by a food allergen, and wherein the composition is administered to the subject less than 4 hours before allergen exposure, less than 4 hours after allergen exposure, or less than 4 hours after manifestation of one or more allergic symptoms in the subject.
US Pat. No. 10,391,158

DNA VECTOR AND TRANSFORMED TUMOR CELL VACCINES

MORPHOGENESIS, INC., Tam...

1. A membrane anchoring protein comprising the amino acid sequence SEQ ID NO: 5 located within the N-terminal signal sequence and the C-terminal anchor region of the protein.
US Pat. No. 10,392,440

METHODS FOR THE PREPARATION OF COMPOUNDS DIRECTED AGAINST INTERLEUKIN-6 RECEPTOR (IL-6R)

Ablynx N.V., Ghent-Zwijn...

1. A method for the preparation of a compound or construct, comprising linking of a polypeptide that specifically binds interleukin-6 receptor (IL-6R) to one or more groups, residues, moieties or binding units,wherein the polypeptide comprises or essentially consists of 4 framework regions (FR1 to FR4) and 3 complementarity determining regions (CDR 1 to CDR3), in which:
CDR1 is SEQ ID NO: 80;
CDR2 is SEQ ID NO: 84; and
CDR3 is SEQ ID NO: 93.
US Pat. No. 10,392,697

COMPOSITE MATRIX USING A HYBRID DEPOSITION TECHNIQUE

UCHICAGO ARGONNE, LLC, C...

1. A method of forming a composite matrix on a porous substrate, the method comprising:(a) subjecting the porous substrate to a first deposition method comprising electrophoretic deposition (EPD) to apply a first coating comprising first ceramic or metallic particles and thereby form a coated substrate; and
(b) subjecting the coated substrate to a second deposition method to apply a second coating comprising second ceramic or metallic particles and thereby form the composite matrix, wherein the second deposition method comprises atomic layer deposition (ALD)A,
wherein step (a) further comprises high pressure infiltration, vacuum slurry infiltration, or both,
and the second coating infiltrates the first coating.
US Pat. No. 10,391,159

METHODS AND MATERIALS FOR TREATING CANCER

Mayo Foundation for Medic...

1. A method of treating cancer within a mammal, wherein said method comprises administering to said mammal a composition comprising nucleic acid encoding an HIF-2? antigen, a SOX-10 antigen, and a C-MYC antigen, wherein said composition comprises less than 100 separate nucleic acid molecules.
US Pat. No. 10,392,441

IL-7R-ALPHA SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA

United States of America,...

1. An isolated monoclonal antibody that specifically binds to an extracellular domain of IL-7R?, comprising:a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO: 1 (4A10 VH) and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO: 2 (4A10 VL); or
a VH comprising a HCDR1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO: 3 (2B8 VH) and a VL comprising a LCDR1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO: 4 (2B8VL).
US Pat. No. 10,391,160

DIMETHYL FUMARATE AND VACCINATION REGIMENS

Biogen MA Inc., Cambridg...

1. A method of treating multiple sclerosis in a human subject in need thereof, said method comprising:(a) administering to the subject a first dose of a pharmaceutical composition for a first dosing period, wherein the pharmaceutical composition comprises a fumarate agent selected from the group consisting of monomethyl fumarate, a pharmaceutically acceptable salt of monomethyl fumarate, dimethyl fumarate, and a combination thereof;
(b) administering a vaccine to the subject, wherein the subject receives the vaccine during the first dosing period; and
(c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period, wherein: (i) the second dosing period is after the first dosing period, and (ii) the second dosing period is initiated within one day of the end of the first dosing period;
wherein the second dose is the same as the first dose, and the first dose and the second dose are administered daily;
wherein the multiple sclerosis is a relapsing form of multiple sclerosis;
wherein the vaccine is an inactive vaccine; and
wherein the first dose is a therapeutically effective amount of monomethyl fumarate, a pharmaceutically acceptable salt of monomethyl fumarate, dimethyl fumarate, or a combination thereof.
US Pat. No. 10,392,442

USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT

Bristol-Myers Squibb Comp...

1. A method for treating a subject afflicted with a tumor comprising administering the subject in need thereof an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity (“an anti-PD-1 antibody”) in combination with varlilumab, wherein the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, MEDI0680, and BGB-A317.
US Pat. No. 10,393,723

METHOD TO REPRESENT METAL CONTENT IN CRUDE OILS, REACTOR FEEDSTOCKS, AND REACTOR PRODUCTS

ASPEN TECHNOLOGY, INC., ...

1. A computer-implemented method of characterizing a chemical composition of crude oil, said method comprising:by a processor:
a. providing physical and chemical property data for organometallic classes, segment types associated with the organometallic classes, and segment number ranges of the segment types;
b. providing characterization data of a crude oil;
c. determining at least one organometallic class and at least one organometallic subclass present in the crude oil based on (i) the provided physical and chemical property data for the organometallic classes and (ii) the provided characterization data of the crude oil;
d. determining at least one segment type and at least one segment number range bound to the determined at least one organometallic class present in the crude oil based on (i) the provided physical and chemical property data for the segment types and the segment number ranges and (ii) the provided characterization data of the crude oil;
e. determining a relative ratio between each of the at least one organometallic class that forms a chemical composition representative of the crude oil, such that the determined relative ratio, the determined at least one organometallic class, the determined at least one organometallic subclass, the determined at least one segment type, and the at least one segment number range form a characterization of the metal content and the chemical composition of the crude oil; and
f. controlling refinery process operations using the formed characterization of the metal content and the chemical composition.
US Pat. No. 10,392,443

DIAGNOSTIC AND THERAPEUTIC TOOL FOR CANCER

Agency for Science, Techn...

1. A method of treating a hepatocellular carcinoma in a subject in need thereof comprisingdetermining the level of extracellular form of Agrin in an extracellular fluid obtained from the subject,
wherein an increased level of the extracellular form of Agrin in the extracellular fluid is indicative of a presence or progression of the cancer,
wherein an increased level is determined by comparison of the level of extracellular form of Agrin in the subject with the extracellular form of Agrin in a non-diseased subject; and
administering a therapeutically effective amount of an anti-Agrin agent to the subject determined to have the presence or progression of the cancer, wherein the anti-Agrin agent is selected from the group consisting of neutralizing antibody Agrin antibody (D-2) and neutralizing antibody anti-Agrin antibody MAB5204.
US Pat. No. 10,391,162

ZIKA RNA VACCINES

ModernaTX, Inc., Cambrid...

1. A Zika virus (ZIKV) immunogenic composition, comprising:a messenger ribonucleic acid (mRNA) polynucleotide having an open reading frame encoding a ZIKV antigenic polypeptide formulated in a lipid nanoparticle.
US Pat. No. 10,391,418

APPARATUS FOR VACUUM PURIFICATION

Merck Patent GmbH, Darms...

1. Apparatus for the sublimation of chemical compounds, comprising an oven (1), a sublimer unit (2), a condensation unit (3), which is in contact with the sublimer unit, a rotation drive (4) for rotation of the sublimer and condensation units, and a vacuum pump or vacuum-pump system (6), characterised in that the apparatus has, between the rotating part and the fixed part, a rotation coupling (5), which is selected from a rotary feedthrough with ferrofluidic seal or a double- or triple-acting mechanical face seal.
US Pat. No. 10,392,444

TUMOR ANTIGEN SPECIFIC ANTIBODIES AND TLR3 STIMULATION TO ENHANCE THE PERFORMANCE OF CHECKPOINT INTERFERENCE THERAPY OF CANCER

Oncoquest, Inc., Edmonto...

1. A method for inhibiting growth of a cancer expressing MUC1 on the cancer cell surface in a patient comprising administering to said patient a therapeutic monoclonal antibody specific to MUC1, a TLR3 agonist, and an anti-PD-L1 antibody, wherein:the therapeutic monoclonal antibody specific to MUC1 is (1) monoclonal antibody AR20.5; or (2) a monoclonal IgE antibody having a heavy chain variable region encoded by SEQ ID NO: 1 and a light chain variable region encoded by SEQ ID NO: 2;
the TLR3 agonist is polyICLC; and
the anti-PD-L1 antibody is monoclonal antibody 10F.9G2.
US Pat. No. 10,391,163

BIRD FLU VACCINE COMBINATION COMPRISING VIRUS-LIKE PARTICLES AND NOVEL ADJUVANTS

Academia Sinica, Taipei ...

1. An adjuvanted influenza vaccine composition with adjuvants, comprising:(a) an influenza virus-like particle (VLP) a therapeutically effective amount against influenza infection, comprising:
(i) influenza M1, influenza M2, influenza hemagglutinin (HA), and influenza neuraminidase (NA) proteins; and
(b) the adjuvants, comprising:
(1) a recombinant capsid VP3 protein (rVP3) of foot-and-mouth disease virus; and
(2) alum.
US Pat. No. 10,391,419

ISOLATION AND PURIFICATION OF CONJUGATED ESTROGENS

NOSTRUM PHARMACEUTICALS. ...

1. A method for preparing purified conjugated estrogens comprising subjecting a mass of pregnant's mare urine which has been dried to a moisture content of less than 2% by weight to supercritical fluid extraction (“SFE”) in a supercritical fluid extraction vessel using supercritical carbon dioxide as the fluid phase to remove impurities present therein and isolating purified conjugated estrogens therefrom.
US Pat. No. 10,391,676

FIBER-REINFORCED MULTILAYERED PELLET, MOLDED ARTICLE MOLDED THEREFROM, AND METHOD OF PRODUCING FIBER-REINFORCED MULTILAYERED PELLET

Toray Industries, Inc., ...

1. A fiber-reinforced multilayered pellet comprising:a sheath layer; and
a core layer,
the sheath layer comprising a resin composition comprising a thermoplastic resin (a1) and a fibrous filler (b1), wherein the fibrous filler (b1) has a weight-average fiber length (Lw) of 0.1 mm to less than 0.5 mm and a weight-average fiber length/number-average fiber length ratio (Lw/Ln) of 1.0 to less than 1.8,
the core layer comprising a resin composition comprising a thermoplastic resin (a2) and a fibrous filler (b2), wherein the fibrous filler (b2) has a weight-average fiber length (Lw) of 0.5 mm to less than 15.0 mm and a weight-average fiber length/number-average fiber length ratio (Lw/Ln) of 1.8 to less than 5.0.
US Pat. No. 10,392,445

TUMOR NECROSIS FACTOR (TNF) FAMILY LIGAND TRIMER-CONTAINING ANTIGEN-BINDING MOLECULES

Hoffmann-La Roche Inc., ...

1. A tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecule comprising(a) at least one antigen-binding domain comprising an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH) capable of specific binding to a target cell antigen wherein the target cell antigen is Fibroblast Activation Protein (FAP) and
(b) a first and a second polypeptide that are linked to each other by a disulfide bond,
wherein the first polypeptide comprises two ectodomains of a TNF ligand family member or a fragment thereof that are connected to each other by a peptide linker and the second polypeptide comprises only one ectodomain of the TNF ligand family member or a fragment thereof, wherein the TNF ligand family member is 4-1BBL and wherein the antigen-binding molecule activates the NF?B signaling pathway.
US Pat. No. 10,391,164

VACCINES FOR HSV-2

IMMUNE DESIGN CORP., Sea...

1. A method of generating an immune response in a subject comprising administering to the subject an immunogenic pharmaceutical composition comprising:(i) (a) an immunogenic fragment of an HSV-2 UL19 polypeptide wherein the immunogenic fragment comprises the amino acid sequence set forth in SEQ ID NO: 12, wherein the immunogenic fragment lacks at least 75% of amino acids 1-450 of SEQ ID NO: 4 and lacks at least 75% of amino acids of 1055-1374 of SEQ ID NO: 4, or an immunogenic variant thereof that retains at least 90% amino acid identity over the full length of the immunogenic fragment;
(b) UL25, wherein said UL25 comprises the amino acid sequence set forth in SEQ ID NO: 5 or an immunogenic fragment thereof comprising at least 15 contiguous amino acids of SEQ ID NO: 5; and
(ii) a monoacid lipid A (MALA) adjuvant.
US Pat. No. 10,392,446

COMPOSITIONS AND METHODS TO MODIFY CELLS FOR THERAPEUTIC OBJECTIVES

FRED HUTCHINSON CANCER RE...

1. A method of selectively transfecting T cells with a polynucleotide in vivo through receptor-mediated endocytosis wherein the transfecting results in in vivo cancer cell killing, the method comprising:Infusing a nanocarrier that is less than about 100 nm in diameter into the bloodstream of a subject wherein the nanocarrier comprises
(i) a negatively-charged coating surrounding a porous core comprising mesoporous silica or a polymer matrix;
(ii) a lymphocyte-directing agent extending from the surface of the nanocarrier wherein the lymphocyte-directing agent comprises a binding domain consisting of an ScFv fragment of a CD3 antibody or an ScFv fragment of a CD8 antibody that induces receptor-mediated endocytosis upon binding to CD3 or CD8 on the surface of a T cell; and
(iii) a polynucleotide encoding a chimeric antigen receptor (CAR) targeting agent within the pores of the core wherein upon introduction into a transfected T cell, the polynucleotide results in transcription and resulting translation of the CAR targeting agent;
thereby selectively transfecting T cells with the polynucleotide in vivo through receptor-mediated endocytosis wherein the transfecting results in in vivo cancer cell killing.
US Pat. No. 10,391,165

RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE VECTORS

ALBERT EINSTEIN COLLEGE O...

1. A method of eliciting an immune response in a first subject against an HSV-2 and/or HSV-1 infection, comprising effectuating passive transfer to the first subject of an amount of a product from a second subject immunized with HSV-2 having a deletion of the entire HSV-2 glycoprotein D-encoding gene in the genome thereof and wherein said HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating said HSV-2 in a complementing cell expressing said HSV-1 glycoprotein D, wherein the product comprises antibodies induced thereby, effective to elicit an immune response against an HSV-2 and/or HSV-1 infection in the first subject.
US Pat. No. 10,395,776

SYSTEMS AND METHODS FOR AUTOMATICALLY DETERMINING MYOCARDIAL BRIDGING AND PATIENT IMPACT

HeartFlow, Inc., Redwood...

1. A computer-implemented method for determining or predicting systolic compression of a patient, the method comprising:receiving one or more patient-specific images of a patient's heart;
computationally generating a patient-specific model using the one or more received patient-specific images, the patient-specific model representing at least a portion of the patient's myocardium and an epicardial coronary artery of the patient;
computationally detecting, in the patient-specific model, a segment of the epicardial coronary artery that is inside, at least partially surrounded by, or adjacent to a surface of the modeled myocardium;
computing systolic compression of the segment of the epicardial coronary artery that is inside, at least partially surrounded by, or adjacent to a surface of the modeled myocardium;
determining one or more patient-related hemodynamic characteristics associated with the patient;
determining and storing an association between the computed systolic compression of the segment and the one or more patient-related hemodynamic characteristics;
receiving one or more hemodynamic characteristics associated with an individual;
determining a systolic compression associated with the individual's coronary artery, based on the one or more received hemodynamic characteristics associated with the individual and the association between the computed systolic compression and the one or more patient-related hemodynamic characteristics.
US Pat. No. 10,392,448

METHOD FOR GRAFTING A CARBOXYLIC ACID ESTER FUNCTION ONTO AN UNSATURATED POLYMER

COMPAGNIE GENERALE DES ET...

1. A composition which comprises a filler and a polymer obtained by synthesizing an unsaturated polymer comprising at least one carboxylic acid ester function along the polymer chain, which comprises reacting a 1,3-dipolar compound with at least one unsaturation of an unsaturated polymer, which 1,3-dipolar compound comprises a group Q and a group B connected to one another by a group A in which:Q comprises a dipole containing at least one nitrogen atom,
B represents a carboxylic acid ester function, and
A is an atom or a group of atoms connecting Q to B.
US Pat. No. 10,393,729

PRENATAL SCREENING

Map IP Holding Limited, ...

1. A method of detecting a fetal aneuploidy comprising:subjecting a neat or dilute, unprocessed maternal urine sample obtained from a pregnant woman between 12-14 weeks gestation to direct mass spectral analysis, wherein the mass spectral analysis is matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS); and
comparing normalised patterns resulting from said analysis to normalised mass spectral patterns in a range of 6,000-14,000 m/z obtained from normal pregnancies to determine whether said normalised patterns from said sample are indicative of a fetal aneuploidy,
wherein the normalised patterns of mass spectra are determined by an automated quantitative method that can distinguish between a normalised mass spectrum of a urine sample from a pregnant woman with a non-aneuploid fetus and the normalised mass spectral pattern of a urine sample from a pregnant woman with an aneuploidy fetus,
wherein the fetal aneuploidy is Downs syndrome, and
wherein the method further comprises:
calculating a Downs syndrome predictive score=(m/z 11400)+(m/z 9200)/(m/z 6700).
US Pat. No. 10,395,777

METHOD AND SYSTEM FOR CHARACTERIZING MICROORGANISM-ASSOCIATED SLEEP-RELATED CONDITIONS

1. A method for characterizing a sleep-related condition associated with microorganisms, the method comprising:determining a microorganism sequence dataset associated with a set of subjects, based on microorganism nucleic acids from samples associated with the set of subjects, wherein the microorganism nucleic acids are associated with the sleep-related condition;
collecting, for the set of subjects, supplementary data associated with the sleep-related condition;
determining at least one of a set of microbiome composition features and a set of microbiome functional features associated with the set of subjects, based on the microorganism sequence dataset;
generating a sleep-related characterization model based on the supplementary data and the at least one of the set of microbiome composition features and the set of microbiome functional features, wherein the sleep-related characterization model is associated with the sleep-related condition;
determining a sleep-related characterization for a user for the sleep-related condition based on the sleep-related characterization model; and
providing a therapy to the user for facilitating improvement of the sleep-related condition, based on the sleep-related characterization.
US Pat. No. 10,391,167

MUCOSAL VACCINE COMPOSITION

NITTO DENKO CORPORATION, ...

1. A method for inducing humoral immunity in a human or animal, comprising:administering to the human or animal a mucosal vaccine composition to a mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, the mucosal vaccine composition comprising:
at least one antigen derived from a pathogen; and
as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Pantoea, Acetobacter, Zymomonas, and Xanthomonas, or a salt of the lipopolysaccharide,
wherein:
a mass ratio between a total mass of the adjuvant and a total mass of the antigen is 0.002 to 500; and
the mucosal vaccine composition is administered in an amount effective to induce humoral immunity in the human or animal.
US Pat. No. 10,392,706

GALVANIZED STEEL SHEET AND METHOD FOR PRODUCING THE SAME

JFE STEEL CORPORATION, T...

1. A galvanized steel sheet comprising a steel sheet and a galvanized coating layer formed on the steel sheet,wherein the coating layer includes an oxide layer in a surface layer, the oxide layer having an average thickness of 20 nm or more, and
the oxide layer comprises Zn, O, H, S, C, P, and unavoidable impurities, and contains 50 mg/m2 or more of Zn, 5 mg/m2 or more of S, 0.2 mg/m2 or more of C, and 0.2 mg/m2 or more of P.
US Pat. No. 10,391,168

ANTI-CD70 COMBINATION THERAPY

UNIVERSITY OF BERN, (CH)...

1. A method of treating a subject with chronic myelogenous leukemia (CML), the method comprising administering to the subject an effective amount of an anti-CD70 antibody or antigen binding fragment thereof that binds to CD70 and inhibits the binding of CD70 to CD27, and a BCR-ABL1 tyrosine kinase inhibitor, thereby treating the subject, wherein the antibody comprises a heavy chain variable domain comprising HCDR1, HCDR2, and HCDR3 regions, and a light chain variable domain comprising LCDR1, LCDR2, and LCDR3 regions, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 regions comprise the amino acid sequences set forth in SEQ ID NOs: 1, 2, 3, 4, 5, and 6, respectively.
US Pat. No. 10,392,707

STEEL FOR CARBURIZING, CARBURIZED STEEL COMPONENT, AND METHOD OF PRODUCING THE SAME

NIPPON STEEL CORPORATION,...

1. A steel for a carburizing comprising as a chemical composition, by mass %,C: 0.07% to 0.13%,
Si: 0.0001% to 0.50%,
Mn: 0.0001% to 0.80%,
S: 0.0001% to 0.100%,
Cr: more than 1.30% to 5.00%,
B: 0.0005% to 0.0100%,
Al: 0.105% to 0.200%,
N: 0.0030% to 0.0100%,
Ti: limited to 0.020% or less,
P: limited to 0.050% or less,
O: limited to 0.0030% or less, and
a balance consisting of iron and unavoidable impurities, wherein:
amounts expressed in mass % of each element in the chemical composition satisfy simultaneously a following Equation 1 as a hardness parameter, a following Equation 2 as a hardenability parameter, and a following Equation 3 as an AlN precipitation parameter;
a shape is a bar or a wire rod in which a cross section perpendicular to a longitudinal direction is round; and
when a distance from a periphery to a center of the cross section is defined as r in unit of mm, in a metallographic structure of a surface layer which is a portion from the periphery to r×0.01, a ferrite and a pearlite are limited before spheroidizing annealing, by area %, to 10% or less in total, and a balance includes at least one of martensite, bainite, tempered martensite, tempered bainite, and cementites,
0.10 7.5<(0.7×Si+1)×(5.1×Mn+1)×(2.16×Cr+1)<44  (Equation 2)
0.0003
US Pat. No. 10,393,731

CELLULAR-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE

GENTIUM S.R.L., Villa Gu...

1. A method of assessing the potency of a sample batch of defibrotide comprising:growing mammalian cells in culture;
incubating the cells with a solution containing at least one cytotoxic agent and at least one concentration of defibrotide from the sample batch;
measuring the viability of the cells after an incubation period;
comparing the cell viability to the cell viability for a reference batch of defibrotide; and
calculating the potency of the sample batch of defibrotide based on the comparison.
US Pat. No. 10,391,169

METHOD OF TREATING ALLERGIC ASTHMA WITH ANTIBODIES TO IL-6

ALDERBIO HOLDINGS LLC, L...

1. A method of treating allergic asthma by administering an effective dosage of an anti-IL-6 antibody or IL-6 binding antibody fragment comprising a variable light chain polypeptide having CDRs of SEQ ID NO:4, 5 and 6 and a variable heavy chain polypeptide having CDRs of SEQ ID NO:7, 8 or 120, and 9.
US Pat. No. 10,393,732

METHOD OF SCREENING A DRUG SUCH AS INSULIN SECRETAGOGUE

JNC Corporation, Tokyo (...

1. A polynucleotide encoding a fusion protein of preproinsulin and a luciferase,wherein the luciferase is Gaussia luciferase, and
wherein Gaussia luciferase is a protein selected from the group consisting of (a) through (c) below:
(a) a protein comprising the amino acid sequence of SEQ ID NO: 8;
(b) a protein consisting of an amino acid sequence comprising deletion, substitution, insertion and/or addition of 1-10 amino acid residues in the amino acid sequence of SEQ ID NO: 8, and having substantially the same activity as a protein consisting of the amino acid sequence of SEQ ID NO: 8; and
(c) a protein consisting of an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 8, and having substantially the same activity as a protein consisting of the amino acid sequence of SEQ ID NO: 8; and
wherein the preproinsulin consists of a signal peptide of preproinsulin and the polypeptide selected from the group consisting of (i) through (k) below:
(i) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4;
(j) a polypeptide comprising a polypeptide consisting of an amino acid sequence comprising deletion, substitution, insertion and/or addition of 1-10 amino acid residues in the amino acid sequence of SEQ ID NO: 4, and having substantially the same activity as the polypeptide consisting of the amino acid sequence of SEQ ID NO: 4; and
(k) a polypeptide comprising a polypeptide consisting of an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 4, and having substantially the same activity as the polypeptide consisting of the amino acid sequence of SEQ ID NO: 4; and
wherein the signal peptide of preproinsulin is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 6.
US Pat. No. 10,391,170

STABLE ANTI-OSMR ANTIBODY FORMULATION

Kiniksa Pharmaceuticals, ...

1. A stable formulation comprising an anti-oncostatin M receptor (OSMR) antibody at a concentration of 100 mg/ml-250 mg/ml and having a pH ranging from approximately 6.0-7.6, wherein the anti-OSMR antibody comprisesa light chain having an amino acid sequence set forth in SEQ ID NO: 2; and
a heavy chain having an amino acid sequence set forth in SEQ ID NO: 1.
US Pat. No. 10,392,452

LIGHT GENERATING MICROCAPSULES FOR SELF-HEALING POLYMER APPLICATIONS

International Business Ma...

1. A self-healing polymeric material comprising:a polymeric matrix material;
a plurality of monomer mixture microcapsules dispersed in the polymeric matrix material, each monomer mixture microcapsule of the plurality of monomer mixture microcapsules encapsulating a mixture of materials that includes monomers and a photoinitiator; and
a plurality of light generating microcapsules dispersed in the polymeric matrix material, each light generating microcapsule of the plurality of light generating microcapsules encapsulating multiple reactants that undergo a chemiluminescent reaction, wherein each light generating microcapsule comprises an outer shell and an inner shell,
wherein the chemiluminescent reaction generates a photon having a wavelength within a particular emission range that is consistent with an absorption range of the photoinitiator and wherein the chemiluminescent reaction occurs without rupture of the outer shell of the light generating microcapsules.
US Pat. No. 10,391,171

MULTI-SPECIFIC ANTIBODIES FOR CROSS-NEUTRALIZATION OF MULTIPLE FILOVIRUS GLYCOPROTEINS

Albert Einstein College o...

1. A composition comprising (1) a first single chain variable fragment (scFv) comprising at least one complementarity-determining region (CDR) directed to a membrane glycoprotein pre-fusion core of a first species of filovirus, which first scFv is covalently joined to (2) a first polypeptide of an immunoglobulin G (IgG) comprising at least one CDR directed to a membrane glycoprotein pre-fusion core of a second species of filovirus, wherein the first species of filovirus and second species of filovirus are different species, wherein the first scFv comprises (i) SEQ ID NOS: 9 and 11, or (ii) SEQ ID NOS: 13 and 15, and wherein the IgG comprises (i) SEQ ID NOS: 13 and 15, or SEQ ID NOS: 9 and 11, respectively.
US Pat. No. 10,392,453

PRODUCTION METHOD FOR OLEFIN-POLYMERIZATION CATALYST AND PRODUCTION METHOD FOR OLEFIN POLYMER

TOHO TITANIUM CO., LTD., ...

1. A method for producing an olefin polymerization catalyst comprising bringing a solid catalyst component for olefin polymerization, a vinylsilane compound, an organosilicon compound, and an organoaluminum compound into contact with each other in an inert organic solvent under an inert gas atmosphere in the absence of a compound represented by a general formula (I), wherein a washing treatment is not performed after the vinylsilane compound has been added to a reaction system, the solid catalyst component comprises a magnesium compound, a titanium halide compound, and an electron donor compound that does not comprise a phthalic acid ester structure, and comprises a diol skeleton, and the organosilicon compound does not comprise a vinyl group, and comprises at least one group selected from an alkoxy group and an amino group,CH2?CH—R1  (I)
wherein R1 is a hydrogen atom or a hydrocarbon residue having 1 to 20 carbon atoms,
wherein the vinylsilane compound is a compound represented by a general formula (II),
(CH2?CH—)SiR2R3R4(II)
wherein R2, R3, and R4 are independently a halogen atom, or a group selected from a group derived from a saturated hydrocarbon compound having 1 to 10 carbon atoms, a group derived from a halogen-containing saturated hydrocarbon compound having 1 to 10 carbon atoms, a group derived from an aromatic hydrocarbon compound having 6 to 20 carbon atoms, and a group derived from a halogen-containing aromatic hydrocarbon compound having 6 to 20 carbon atoms, provided that R2, R3, and R4 are either identical to or different from each other.
US Pat. No. 10,392,710

BRIGHTENING AND PASSIVATION OF STAINLESS STEEL SURFACES

1. A passivating and brightening aqueous composition, comprising water and the following dissolved components:(A) at least one acid which does not contain fluorine;
(B) at least one fluorine containing inorganic compound;
(C) at least one substance containing a peroxy moiety; and
(D) at least one organic polyol compound containing more than two hydroxyl groups with at least 3, but not more than 8 carbon atoms.
US Pat. No. 10,392,455

PROCESS FOR CONTROLLING THE POLYMER COMPOSITION OF AN ETHYLENE COPOLYMER OBTAINED BY A CATALYST SYSTEM COMPRISING A TRANSITION METAL CATALYST COMPONENT AND A ZIEGLER CATALYST COMPONENT

Basell Polyolefine GmbH, ...

1. A method of preparing an ethylene copolymer composition comprising:forming the ethylene copolymer composition by copolymerizing ethylene and at least one other olefin in a single stage in the presence of a polymerization catalyst system comprising:
(i) at least one late transition metal catalyst component (A) selected from the group consisting of iron, nickel, palladium and cobalt,
(ii) at least one Ziegler catalyst component (B), and
(iii) at least one activating compound (C),
wherein the ethylene copolymer composition has a vinyl group concentration per 1000 carbons of 0.96 or less,
wherein the ethylene copolymer composition comprises a first ethylene copolymer component derived from the at least one late transition metal catalyst component (A) and a second ethylene copolymer component derived from the at least one Ziegler catalyst component (B),
wherein the forming step further includes the step of:
adding an alkyl alkoxy silane or a dialkyl ether, wherein the relative amount of the first ethylene copolymer component derived from the at least one late transition metal catalyst component (A) is increased relative to the second ethylene copolymer component, or adding a saturated halogenated hydrocarbon, wherein the relative amount of the second ethylene copolymer component derived from the at least one Ziegler catalyst component (B) is increased relative to the first ethylene copolymer component;
wherein the ratio of (C) to (A) is from 20,000:1 to 1:1, and the ratio of (B) to (A) is from 500:1 to 1:100.
US Pat. No. 10,393,735

PROCESSING OF FLUIDS CONTAINING INTERFERING PARTICLES

KONINKLIJKE PHILIPS N.V.,...

1. A device for processing a fluid containing interfering particles (C), the device comprising:a processing chamber containing the fluid and magnetic particles (MP, MPB), the processing chamber comprising a blocking zone (BZ, BZ?) formed by distribution of the magnetic particles for physically imped the interfering particles to filter out and control distribution of the interfering particles within the processing chamber during the processing of the fluid to alter interference caused by the interfering particles; and
a magnetic field generator for generating a magnetic field that provides, at least in part, the distribution of the magnetic particles (MP, MPB) forming the blocking zone (BZ, BZ?) within the processing chamber,
wherein the mean distance between the magnetic particles (MP, MPB) and/or clusters (CL) of the magnetic particles of the blocking zone (BZ, BZ?) is less than or equal to about five times the mean diameter of the interfering particles (C).
US Pat. No. 10,391,173

ANTI-AR AGENT AND RADIATION THERAPY FOR ANDROGEN RECEPTOR POSITIVE CANCER

THE CLEVELAND CLINIC FOUN...

1. A method of treating cancer comprising:a) determining that a subject has androgen receptor positive breast cancer cells;
b) treating said subject with an anti-androgen receptor agent under conditions such that at least some or most or all of said androgen receptor positive cancer cells are sensitized to radiation therapy; and
c) treating said subject with radiation therapy, wherein said radiation therapy is performed at least 1 hour after said treating with said anti-androgen receptor agent, and wherein said treating causes at least a portion of said androgen receptor positive cancer cells to die.
US Pat. No. 10,392,712

CHEMICAL INHIBITION OF PITTING CORROSION IN METHANOLIC SOLUTIONS CONTAINING AN ORGANIC HALIDE

Baker Hughes, a GE compan...

1. A methanolic solution comprising:water;
methanol;
at least one organic halide; and
at least one compound selected from the group consisting of organic hydroxyacids containing 2 to 10 carbon atoms with at least one hydroxyl group and at least one carboxylic acid group, and alkaline metal salts thereof, and amine salts thereof, and combinations thereof; where:
the methanol proportion ranges from about 5 to about 60 wt %;
the at least one organic halide proportion ranges from about 0.5 to about 70 wt %; and
the at least one compound proportion ranges from about 0.5 to about 10 wt %.
US Pat. No. 10,391,176

COMPOSITION, ITS PREPARATION AND METHOD OF USE IN TREATING SKIN DISORDERS

1. A composition comprising:a. zafirlukast;
b. a first and a second polyethylene glycol;
c. (a nonionic hydrophilic ester) PEG 6 caprylic/capric glycerides;
d. an alcohol; and
e. an antioxidant.
US Pat. No. 10,393,739

BIOMARKERS FOR SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY, AND INTENSITY AND FLARE

Oklahoma Medical Research...

1. A method for assessing protein expression levels in a systemic lupus erythematosus (SLE) patient comprising:(a) obtaining a blood, serum or plasma sample from the SLE patient;
(b) assessing protein expression levels of at least one cytokine from each of (i), (ii), (iii), and (iv), wherein (i) is an innate-type cytokine selected from an interleukin-1 alpha (IL-1?), an interleukin-1 beta (IL-1?), an interferon-alpha (IFN-?), interferon-beta (IFN-?), a granulocyte-colony stimulating factor 3 (G-CSF), interleukin-7 (IL-7), and an interleukin-15 (IL-15), (ii) is a T-helper type-1 (Th1) cytokine selected from an interleukin-2 (IL-2), an interleukin-12 (IL-12), and an interferon-gamma (IFN-?), (iii) is a T-helper type-2 (Th2) cytokine selected from an interleukin-4 (IL-4), an interleukin-5 (IL-5), and an interleukin-13 (IL-13), and (iv) is a T-helper type-17 (Th17) cytokine selected from an interleukin-6 (IL-6), an interleukin-17A (IL-17A), an interleukin-21 (IL-21), and an interleukin-23 (IL-23); and
(c) assessing protein expression levels of each molecule from each of (v), (vi), (vii), and (viii), wherein (v) comprises the following chemokine(s) or adhesion molecules: a C—X—C motif chemokine ligand 8 (CXCL8)/interleukin-8 (IL-8), a C—X—C motif chemokine ligand 10 (CXCL10)/IFN-gamma-inducible protein 10 (IP-10), one or both of a C—C motif chemokine ligand 5 (CCL5) and regulated on activation normal T cell expressed and secreted (RANTES), a C—C motif chemokine ligand 2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1), a C—C motif chemokine ligand 7 (CCL7)/monocyte chemoattractant protein-3 (MCP-3), a C—C motif chemokine ligand 3 (CCL3)/macrophage inflammatory protein-1 alpha (MIP-1?), a C—C motif chemokine ligand 4 (CCL4)/macrophage inflammatory protein-1 beta (MIP-1?), a C—X—C motif chemokine ligand 1 (CXCL1)/growth-regulated oncogene-alpha (GRO-?), a C—X—C motif chemokine ligand 9 (CXCL9)/monokine induced by interferon-gamma (MIG), an eotaxin, an Intercellular Adhesion Molecule 1 (ICAM-1), and an E-selectin, (vi) comprises the following tumor necrosis factor receptor (TNFR) superfamily member molecules: a tumor necrosis factor alpha (TNF-?), a tumor necrosis factor receptor I (TNFRI), a tumor necrosis factor receptor II (TNFRII), a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a first apoptosis signal (Fas), a first apoptosis signal ligand (FasL), a B-lymphocyte stimulator (BLyS), a proliferation-inducing ligand (APRIL), and a nerve growth factor-beta (NGF?), (vii) comprises the following regulatory mediator molecules: an interleukin-10 (IL-10), a transforming growth factor beta (TGF-?), a C—X—C motif chemokine ligand 12 (CXCL12)/stromal cell-derived factor 1 (SDF-1), and an interleukin-1 receptor antagonist (IL-1RA), and (viii) comprises the following systemic lupus erythematosus (SLE) mediator molecules: a leukemia inhibitor factor (LIF), a plasminogen activator inhibitor-1 (PAI-1), a platelet-derived growth factor subunit beta homodimer (PDGF-BB), a leptin, a stem cell factor (SCF), and an interleukin-2 receptor alpha chain (IL-2RA).
US Pat. No. 10,393,740

METHODS FOR IDENTIFYING MODULATORS OF CALCIUM-SENSING RECEPTORS

MARS, INCORPORATED, McLe...

1. A method for identifying a compound that modulates biological activity of a calcium-sensing receptor (CaSR) comprising(a) contacting one or more compound at a concentration of no more than 30 mM with a CaSR, wherein the CaSR is a feline CaSR comprising the amino acid sequence set forth in SEQ ID NO:4 or a canine CaSR comprising the amino acid sequence set forth in SEQ ID NO:5,
(b) determining biological activity of the CaSR, and
(c) selecting the compound as a compound that modulates the biological activity of a CaSR, if the compound increases the biological activity of the CaSR.
US Pat. No. 10,391,178

PREMIX OF CRYSTALLINE RALTEGRAVIR POTASSIUM SALT AND A PROCESS FOR THE PREPARATION THEREOF

Mylan Laboratories Limite...

1. A process for preparing a premix of raltegravir potassium form 3, the process comprising the steps of:(a) dissolving raltegravir free base in an ester solvent to create a solution;
(b) adding a potassium source to the solution;
(c) adding a pharmaceutical excipient to form a reaction mass;
(d) cooling the reaction mass; and
(e) isolating the raltegravir potassium form 3 premix from the reaction mass, the raltegravir potassium form 3 premix comprising raltegravir potassium form 3 and the pharmaceutical excipient, wherein the pharmaceutical excipient is at least one of microcrystalline cellulose, polysorbate, mannitol, or hydroxypropyl methylcellulose.
US Pat. No. 10,392,461

MODIFIED POLYOLEFIN PARTICLES AND METHODS FOR PRODUCING THE SAME

MITSUI CHEMICALS, INC., ...

1. Modified polyolefin particles obtained by grafting a monomer having an ethylenically unsaturated group and a polar functional group in the same molecule to a polymer including one, or two or more ?-olefins selected from C2-18 ?-olefins and having a melting point of not less than 50° C. and less than 250° C., the modified polyolefin particles having an average particle size of 0.2 mm to 10 mm and satisfying the following requirements (1) to (3):(1) the amount of grafting x by the monomer having an ethylenically unsaturated group and a polar functional group in the same molecule is not less than 0.5 wt % and not more than 20 wt %;
(2) the amount of grafting x (wt %) by the monomer having an ethylenically unsaturated group and a polar functional group in the same molecule, and the intrinsic viscosity [?] (dl/g) measured in decalin at 135° C. satisfy the relation:
log10[?]?0.1-0.15x; and
(3) the modified polyolefin particles have a gel content of less than 1 wt %;
wherein the gel content is determined by placing approximately 0.3 g of the modified polyolefin particles into a 330 mesh metal gauge, adding 100 ml of xylene to the modified polyolefin particles in the gauge, heating the mixture under reflux for 2 hours, and calculating a ratio of the weight of undissolved components retained in the metal gauge to the weight of the whole of the modified polyolefin particles, and is obtained as the ratio.
US Pat. No. 10,393,741

COMPOSITIONS AND METHODS FOR THE DETECTION OF ANAPLASMA PLATYS

Ohio State Innovation Fou...

1. A method for diagnosing an infection with Anaplasma platys in a subject comprising the steps of: (a) providing a test sample from the subject; (b) providing an isolated or purified P44 protein of Anaplasma platys; (c) contacting the test sample with the P44 protein; and (d) assaying for the formation of a complex between antibodies in the test sample and the P44 protein, wherein formation of said complex is indicative of infection with Anaplasma platys, wherein the Anaplasma platys P44 protein comprises SEQ ID NO: 39, SEQ ID NO: 92 or SEQ ID NO:44.
US Pat. No. 10,393,742

METHOD AND PEPTIDES FOR THE DETECTION OF CHLAMYDIA SUIS

UNIVERSITEIT GENT, Ghent...

1. An in vitro method for detecting the presence of Chlamydia suis antibodies in a subject, comprising:providing a biological sample from the subject, and
analyzing the sample for the presence of antibodies against the peptide of SEQ ID NO: 1 (GTKDASID), or a peptide of an amino acid sequence being at least 75% identical thereto;and/or against a peptide of SEQ ID NO: 2 (SQQSSIAS), or a peptide of an amino acid sequence being at least 75% identical thereto.
US Pat. No. 10,392,463

ACRYLIC RESIN COMPOSITION, AND MOLDED PRODUCT AND FILM MADE FROM SAME

KANEKA CORPORATION, Osak...

1. A resin composition comprising:an acrylic resin; and
a graft copolymer having a gel content of 65 to 84%,
wherein the graft copolymer comprises:
a first hard polymer comprising 40 to 100 wt % of a methacrylate ester unit (a-1), 60 to 0 wt % of a monomer unit (a-2) having a double bond copolymerizable with the methacrylate ester unit, and 0.01 to 10 parts by weight of a polyfunctional monomer unit per 100 parts by weight of a total amount of (a-1) and (a-2),
a soft polymer comprising 60 to 100 wt % of an acrylate ester unit (b-1), 0 to 40 wt % of a monomer unit (b-2) having a double bond copolymerizable with the acrylate ester unit, and 0.1 to 5 parts by weight of a polyfunctional monomer unit per 100 parts by weight of a total amount of (b-1) and (b-2); and
a second hard polymer comprising 60 to 100 wt % of a methacrylate ester unit (c-1),
40 to 0 wt % of a monomer unit (c-2) having a double bond copolymerizable with the methacrylate ester unit, and 0 to 10 parts by weight of a polyfunctional monomer unit per 100 parts by weight of a total amount of (c-1) and (c-2),
wherein at least a part of the first hard polymer is coated with the soft polymer,
wherein the second hard polymer is grafted on the first hard polymer and/or the soft polymer, and
wherein the first hard polymer has a primary alkylthio group and/or a secondary alkylthio group.
US Pat. No. 10,391,694

METHOD OF PRODUCING FILM

KANEKA CORPORATION, Osak...

1. A method of producing a film, the method comprising:melting and kneading a thermoplastic resin composition having a relaxation modulus of not less than 100 Pa and not more than 1500 Pa, the relaxation modulus being measured under conditions of a temperature of 260° C., distortion of 1%, and a relaxation time of 1 second; and
performing extrusion molding of the thermoplastic resin composition using a T die to form the film,
wherein the thermoplastic resin composition contains an acrylic resin and a rubber particle.
US Pat. No. 10,392,464

THERMOPLASTIC RESIN, METHOD OF PREPARING THERMOPLASTIC RESIN, AND THERMOPLASTIC RESIN COMPOSITION INCLUDING THERMOPLASTIC RESIN

LG CHEM, LTD., Seoul (KR...

1. A thermoplastic resin, comprising: a core prepared by graft-polymerizing 40 to 70% by weight of a conjugated diene rubbery polymer with 7.5 to 30% by weight of a total of monomers comprising an aromatic vinyl compound and a vinyl cyanide compound; and a shell enclosing the core and prepared by graft-polymerizing the conjugated diene rubbery polymer with 15 to 45% by weight of a total of monomers comprising an aromatic vinyl compound and a vinyl cyanide compound,wherein the vinyl cyanide compound of the monomers constituting the core is comprised in an amount of 0.01 to 20% by weight based on 100% by weight of a total of the monomers of the core, and
the vinyl cyanide compound of the monomers constituting the shell is comprised in an amount of greater than 25% by weight to 90% by weight or less based on 100% by weight of a total of the monomers of the shell,
wherein the conjugated diene rubbery polymer is a mixture of a rubbery polymer (A) having a gel content of 60 to 75% by weight and a rubbery polymer (B) having a gel content of 80 to 95% by weight.
US Pat. No. 10,393,744

PEPTIDES FOR TARGETING COLORECTAL CANCER, AND MEDICAL USE THEREOF

UNIVERSITY OF ULSAN FOUND...

1. A method for diagnosing colorectal cancer, comprising:applying a composition comprising the peptide of SEQ ID NO: 15 to a patient of having a colorectal cancer; and
identifying the presence of the colorectal cancer.
US Pat. No. 10,392,465

POLYMERIZED ROSIN COMPOUND AND PRODUCTION METHOD THEREFOR

Arakawa Chemical Industri...

1. A polymerized rosin composition comprising:a rosin dimer component (A) which comprises a bifunctional rosin dimer component (a1) represented by formula (1): ROOC—X—COOR,
wherein X represents a rosin dimer residue derived from resin acid having conjugated double bonds which is at least one selected from the group consisting of abietic acid, neoabietic acid, and palustric acid, and R represents hydrogen, an alkyl group of 1 to 5 carbon atoms, or a benzyl group,
the polymerized rosin composition comprises a content of the bifunctional rosin dimer component (a1) of 91.6% by weight or more, and
a rosin trimer or higher oligomer component (B) of 1.5 to 3.7% by weight,
wherein the rosin dimer component is free of a monofunctional rosin dimer component (a2) having one functional group represented by formula (2): ROOC—, wherein R represents hydrogen, an alkyl group of 1 to 5 carbon atoms, or a benzyl group, and a functional group-free rosin dimer component (a3) free of the functional group represented by formula (2): ROOC—, wherein R represents hydrogen, an alkyl group of 1 to 5 carbon atoms, or a benzyl group.
US Pat. No. 10,393,745

METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER

The USA, as represented b...

1. A method for detecting creatine riboside in an individual, the method comprising:a) obtaining a sample from the individual; and,
b) detecting whether creatine riboside is present in the sample using at least one method selected from the group consisting of:
i) a method comprising column chromatography; and
ii) a method comprising ionizing the sample so that if creatine riboside is present in the sample, creatine riboside ions are created, wherein the creatine riboside ions comprise an ion, or fragment ion, having a mass charge ratio of 264.1196+ or 90.0550+, and using mass spectrometry to detect the creatine riboside ions, if present.
US Pat. No. 10,391,183

INFECTIVITY-ENHANCED CONDITIONALLY-REPLICATIVE ADENOVIRUS AND USES THEREOF

The UAB Research Foundati...

1. A method of providing adenoviral gene therapy to an individual having a cancer comprising tumor cells, the method comprising the steps of:directly administering to the tumor cells a therapeutic dose of an infectivity-enhanced conditionally-replicative adenovirus, wherein said infectivity-enhanced conditionally-replicative adenovirus possesses a modification or a replacement within the fiber protein that leads to enhanced infectivity of the tumor cells as compared to the infectivity of the tumor cells by a wild-type adenovirus without the modification or the replacement, and an early gene whose expression mediates the conditional replication of said infectivity-enhanced conditionally-replicative adenovirus in said tumor cells, wherein said adenovirus has a genome comprising an E1A deletion limited to the 24 nucleotides encoding amino acids 122 to 129 of the adenoviral E1A protein, but otherwise contains all other wild-type E1A nucleotides, and wherein said early gene is conditionally regulated by means selected from the group consisting of a tissue-specific promoter operably linked to said early gene and a mutation in said early gene.
US Pat. No. 10,391,440

METHOD FOR PRODUCING OXYGEN BY VPSA

1. A process for the production of oxygen by adsorption of a stream of atmospheric air employing VPSA comprising at least one adsorber, each adsorber being subjected to the same pressure cycle comprising the following stages:a) production of a first gas stream comprising an oxygen content C1 while charging upstream the adsorber with the stream of atmospheric air,
b) production of a second gas stream comprising an oxygen content C2 c) production of a third gas stream comprising an oxygen content C3 d) elution of the adsorber, from which have emerged the three gas streams produced in stages a), b) and c), with the second gas stream produced in stage b),
e) repressurization of the adsorber which has been subjected to the elution of stage d) with successively at least two streams, a first and a second repressurization stream, having an increasing oxygen content, the first repressurization stream being the third gas stream produced in stage c) and the second repressurization stream being the second gas stream produced in stage b).
US Pat. No. 10,392,466

TWO-COMPONENT POLYURETHANE ADHESIVE COMPOSITION

3M Innovative Properties ...

1. A curable two-component polyurethane adhesive composition comprising:a first component C1 comprising at least one polyol;
a second component C2 comprising at least one isocyanate; and
a polyurethane catalytic system comprising a first bicyclic amine and a second bicyclic amine, wherein the first bicyclic amine is selected to be 1,8-diazabicyclo[5.4.0]undec-7-ene and the second bicyclic amine is selected to be 1,4-diazabicyclo[2.2.2]octane.
US Pat. No. 10,393,746

KIT FOR IMMUNOLOGICAL DETECTION OF TNF-ALPHA, STNFR1 AND IL-8 IN PROSTATE CANCER

Health Research, Inc., B...

1. A kit for use in immunological detection of tumor necrosis factor ?(TNF?), soluble TNF receptor 1 (sTNFR1), interleukin-8 (IL-8), and Prostate Serum Antigen (PSA), wherein the kit comprises one or more sealed containers that comprise monoclonal and/or polyclonal capture antibodies that are specific for TNF?, sTNFR1, IL-8, and PSA, and wherein the kit comprises one or more sealed containers that comprise monoclonal and/or polyclonal detection antibodies that are for use in specifically binding to captured TNF?, sTNFR1, IL-8, and PSA.
US Pat. No. 10,391,184

METHODS AND COMPOSITIONS FOR TREATING BRAIN DISEASES

University of Iowa Resear...

1. A method of delivering a therapeutic agent to the central nervous system of a mammal, comprising administering an immunesuppression agent to the mammal and administering to the mammal's cisterna magna, brain ventricle, subarachnoid space, or intrathecal space an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding a therapeutic agent inserted between a pair of AAV inverted terminal repeats in a manner effective to infect a cell that contacts the cerebrospinal fluid (CSF) of the mammal such that the cell expresses the therapeutic agent in the mammal, wherein the therapeutic agent is tripeptidyl peptidase 1 (TPP1), and wherein the mammal is a primate.
US Pat. No. 10,393,747

DIAGNOSTIC METHOD FOR GASTRIC CANCER

Korea Advanced Institute ...

1. A method comprising:separating haptoglobin from a sample derived from a subject;
separating N-glycan by treating the haptoglobin with an enzyme;
performing mass spectrometry on the separated N-glycan; and
performing quantitative profiling for a result of the mass spectrometry by one or more selected from the group consisting of a receiver-operation characteristic (ROC) curve analysis, and an area-under-the-ROC curve (AUC) analysis on one or more selected from the group consisting of tri-antennary Hex6-HexNAc5-Fuc1 glycan (2151.8 m/z) and tetra-antennary Hex7-HexNAc6-Fuc1 glycan (2516.9 m/z);
identifying that the subject has gastric cancer or a high risk of gastric cancer
when an AUC value of tri-antennary Hex6-HexNAc5-Fuc1 glycan (2151.8 m/z) is 0.9 or higher,
when an AUC value of tetra-antennary Hex7-HexNAc6-Fuc1 glycan (2516.9 m/z) is 0.9 or higher,
when an average of the AUC value of tri-antennary Hex6-HexNAc5-Fuc1 glycan (2151.8 m/z) and the AUC value of tetra-antennary Hex7-HexNAc6-Fuc1 glycan (2516.9 m/z) is 0.9 or higher, or
when a sum of the AUC value of tri-antennary Hex6-HexNAc5-Fuc1 glycan (2151.8 m/z) and the AUC value of tetra-antennary Hex7-HexNAc6-Fuc1 glycan (2516.9 m/z) is 0.9 or higher; and
administering a therapeutic drug to said identified subject for treating gastric cancer.
US Pat. No. 10,391,185

MULTIMODAL ULTRASOUND AND PHOTOACOUSTIC CONTRAST AGENT BASED ON POLYMERIC MICROPARTICLES

Fujifilm VisualSonics, In...

1. A multimodal ultrasound and photoacoustic contrast agent, comprising for use in ultrasound and photoacoustic imaging poly(n-butyl cyanoacrylate) (PBCA) microparticles (microbubbles) having a gas core and carrying at least one photoacoustic agent in its PBCA shell that stabilizes the gas core.
US Pat. No. 10,393,748

METHOD FOR PREDICTING EFFICACY OF C-MET INHIBITOR

SAMSUNG ELECTRONICS CO., ...

1. A method for selecting a subject suitable for the application of a c-Met inhibitor in cancer treatment, comprising:measuring the level of IL-8 in a serum sample from a patient having cancer;
determining the presence of K-RAS and B-RAF mutations in a cancer tissue sample from the patient having cancer;
measuring the level of c-Met expression in a cancer tissue sample from the patient having cancer;
selecting the patient as the subject suitable for the application of a c-Met inhibitor when the level of IL-8 in the serum sample is about 500 pg/ml or higher, no K-RAS or B-RAF mutations are found in the cancer tissue sample, and c-Met is expressed in the cancer tissue sample; and
administering the c-Met inhibitor to the selected patient.
US Pat. No. 10,392,469

EPOXY RESIN COMPOSITIONS FOR PRODUCTION OF STORAGE-STABLE COMPOSITES

Evonik Degussa GmbH, Ess...

11. A composite component, obtained from at least one fibrous carrier and at least one crosslinked epoxy resin composition, wherein said epoxy resin composition is as defined in claim 1.
US Pat. No. 10,393,750

FORMALIN-FIXED ISOTOPE-LABELED REFERENCE STANDARDS AND METHODS FOR FABRICATION AND USE THEREOF

BIOPROXIMITY, LLC, Sprin...

1. A method comprising:characterizing proteomes of a plurality of respective cell lines;
before or after the characterizing, preserving the plurality of respective cell lines by fixation so as to form multiple bio-specimen reference standards, each bio-specimen reference standard having proteins labeled with a minor stable isotope; and
after the preserving to form the bio-specimen reference standards:
selecting one of the bio-specimen reference standards for analyzing a biological sample based at least in part on the characterized proteome or a pathological comparison of the biological sample to the bio-specimen reference standards,
combining a portion of the biological sample with a portion of one of the selected bio-specimen reference standards; and
performing mass spectrometry on the combined portions of the biological sample and the selected bio-specimen reference standard,
wherein the characterizing proteomes of the plurality of respective cell lines is performed separately from the mass spectrometry of the combined portions of the biological sample and the selected bio-specimen reference standard.
US Pat. No. 10,393,751

SPECIFIC PEPTIDE BINDERS TO PROTEINS IDENTIFIED VIA SYSTEMATIC DISCOVERY, MATURATION AND EXTENSION PROCESS

ROCHE SEQUENCING SOLUTION...

1. An isolated artificial peptide binder bound to a target protein, the isolated artificial peptide binder having specific affinity for the target protein, the artificial peptide binder having at least 5 and up to 20 amino acids, the artificial peptide binder selected from a streptavidin binder comprising a sequence selected from the sequences in Tables 1 and 2; a Taq polymerase binder comprising a sequence selected from the sequences in Table 3; a binder to Prostate Specific Antigen (PSA) comprising a sequence selected from the sequences in Table 4; a thrombin binder comprising a sequence selected from the sequences in Table 5; a binder to Tumor Necrosis Factor comprising a sequence selected from the sequences in Table 6; and a binder to Urokinase-type Plasminogen Activator (uPA) comprising a sequence selected from the sequences in Table 7,wherein the artificial peptide binder is one of an N-terminal tag added to a protein, a C-terminal tag added to a protein, and attached to a solid support through a covalent bond,
wherein when the artificial peptide binder is a streptavidin binder, the target protein is streptavidin,
wherein when the artificial peptide binder is a Taq polymerase binder, the target protein is Taq polymerase,
wherein when the artificial peptide binder is a Prostate Specific Antigen (PSA) binder, the target protein is Prostate Specific Antigen (PSA),
wherein when the artificial peptide binder is a thrombin binder, the target protein is thrombin,
wherein when the artificial peptide binder is a binder to Tumor Necrosis Factor, the target protein is Tumor Necrosis Factor, and
wherein when the artificial peptide binder is a binder to Urokinase-type Plasminogen Activator (uPA), the target protein is Urokinase-type Plasminogen Activator (uPA).
US Pat. No. 10,393,752

MASS SPECTROMETRY-CLEAVABLE CROSS-LINKING AGENTS

THE REGENTS OF THE UNIVER...

1. An MS-cleavable cross-linker for mapping intra-protein interactions in a protein, inter-protein interactions in a protein complex or a combination thereof, the MS-cleavable cross-linker comprising:two amine-reactive N-hydroxysuccinimdyl (NHS) ester groups;
a spacer arm with at least one central sulfoxide group, wherein the at least one central sulfoxide group is linked to each of the two amine-reactive N-hydroxysuccinimdyl (NHS) ester groups through at least two methylene groups; and
two symmetric collision-induced dissociation (CID) cleavable bonds on the spacer arm,
wherein each of the two CID cleavable bond is a C—S bond adjacent to the at least one central sulfoxide.
US Pat. No. 10,393,753

HUMAN EXHALED AEROSOL DROPLET BIOMARKER SYSTEM AND METHOD

University of Maryland, C...

1. A method for detecting a biomarker in exhaled breath condensate nanodroplets, comprising the steps of:noninvasively collecting exhaled breath condensate (EBC) nanodroplets from a subject by impacting said nanodroplets into a liquid medium; and
analyzing said nanodroplets utilizing immuno-quantitative polymerase chain reaction (IqPCR) to detect one or more target biomarkers in said nanodroplets.
US Pat. No. 10,391,704

METHOD TO MANUFACTURE A RAZOR HANDLE

The Gillette Company LLC,...

1. A method to manufacture a razor handle, said method comprising the steps of:a) providing a material which is formable by hand
b) forming a handle model from said moldable material by hand
c) creating a 3D point cloud from said handle model
d) creating a 3D CAD file of said 3D point cloud of said handle model
e) creating a connection point for a razor cartridge in said 3D CAD file of said handle
f) 3D printing said connection point and handle.
US Pat. No. 10,393,755

COMPOSITIONS AND METHODS FOR TREATING EYE INFECTIONS AND DISEASE

University of Virginia Pa...

1. A sterile, aqueous pharmaceutical composition for topical administration to an ocular surface, the composition comprising:a peptide, or a pharmaceutically acceptable salt thereof,
wherein the peptide, or a pharmaceutically acceptable salt thereof, has an amino acid sequence consisting of SEQ ID NO: 5,
wherein the C-terminus of the peptide is amidated,
wherein the N-terminus of the peptide is acetylated, and a pharmaceutically acceptable aqueous carrier,
wherein the sterile, aqueous pharmaceutical composition is suitable for topical administration to an ocular surface of a subject, and
wherein the sterile, aqueous pharmaceutical composition is free of any type of enzymatic, chemical or biochemical molecule capable of breakdown of the peptide at its termini that is sequential degradation of the peptide at a terminal end thereof in the absence of the C-terminus amidation and the N-terminus acetylation.
US Pat. No. 10,393,756

METHODS OF TREATING A SUBJECT HAVING HEART FAILURE THAT INCLUDE DETECTING LEVELS OF GALECTIN-3 AND SOLUBLE ST2

Critical Care Diagnostics...

1. A method of treating a subject having heart failure, the method comprising:(a) performing an assay to determine a level of galectin-3 in a biological sample from a subject having heart failure;
(b) comparing the level of galectin-3 in the biological sample of (a) to a reference level of galectin-3;
(c) identifying a subject having an elevated level of galectin-3 in the biological sample of (a) as compared to the reference level of galectin-3;
(d) performing an assay to determine the level of soluble ST2 in a biological sample from the identified subject;
(e) comparing the level of soluble ST2 in the biological sample of (d) to a reference level of soluble ST2; and
(f) administering a beta-adrenergic blocking agent to an identified subject having an elevated level of soluble ST2 in the biological sample of (d) as compared to the reference level of soluble ST2.
US Pat. No. 10,393,757

DIAGNOSTIC DRUG AND DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE

DAINIPPON SUMITOMO PHARMA...

1. A method of treating a test person affected with Alzheimer's disease or having a high possibility of being affected with Alzheimer's disease in the near future comprising the steps of:(1) detecting an S38AA fragment with an anti-S38AA antibody in a sample collected from the test person,
(2) comparing the amount of S38AA fragment in the sample collected from the test person with an amount of S38AA fragment in a sample collected from a normal person,
(3) determining the test person is affected with Alzheimer's disease or has a high possibility of being affected with Alzheimer's disease in the near future when the amount of S38AA fragment in the sample from the test person is high relative to the amount of S38AA fragment in the sample from the normal person, and
(4) administering an agent capable of treating or preventing Alzheimer's disease to the test person who is determined to be affected with Alzheimer's disease or has a high possibility of being affected with Alzheimer's disease in the near future in step (3),
wherein the S38AA is a polypeptide comprising the amino acid sequence shown by SEQ ID NO: 2,
wherein the S38AA fragment is a polypeptide consisting of the S38AA extra-membranous domain or a partial polypeptide thereof,
wherein the antibody is an antibody specifically recognizing an amino acid region selected from the following (a) to (c): (a) the 689-1119th amino acids of the amino acid sequence shown by SEQ ID NO: 2, (b) the 399-688th amino acids of the amino acid sequence shown by SEQ ID NO: 2, and (c) an amino acid region spanning both regions (a) and (b), and
wherein the sample collected from the test person and the sample collected from the normal person are blood.
US Pat. No. 10,391,195

SUPER-ABSORBING POLYMERS WITH RAPID ABSORPTION PROPERTIES AND METHOD FOR PRODUCING THE SAME

Evonik Degussa GmbH, Ess...

1. A method for preparing a low cellulose content absorbent core by selecting a particulate superabsorbent polymer material for incorporating the particulate absorbent polymer material in an absorbent core containing an upper substrate layer, a lower substrate layer and also an absorption layer arranged between the upper and the lower substrate layers, wherein the absorption layer comprises the particulate absorbent polymer material and less than 0.1 g of cellulose fibres per gram of particulate absorbent polymer material, containing the steps ofA) identifying a particulate absorbent polymer material having at least one of the following properties:
i) a maximum APCi×10 sec value ?1.6 for at least one number i selected from the group of integers from 2 to 12; and/or
ii) a value ?12 for the sum total of all APCi×10 sec sec values for all numbers i from the group of integers from 2 to 12;
wherein APCi×10 sec value is defined as follows:
APCi×10 sec value=(QIi×10 sec value)2×PIi×10 sec value, where
the QIi×10 sec sec value is the value of the swell index determined i×10 seconds after adding a 0.9% by weight NaCl solution, and
the PIi×10 sec value is the value of the permeability index determined i×10 seconds after adding the 0.9% by weight NaCl solution; and
B) incorporating the particulate absorbent material in an absorbent core.
US Pat. No. 10,393,758

METHODS FOR TREATING OR AMELIORATING MULTIPLE SCLEROSIS

UNIVERSIDAD DE MALAGA, M...

1. A method for treating or ameliorating multiple sclerosis, the method comprising administering to a subject in need thereof a composition comprising:(1) a protein comprising the amino acid sequence SEQ ID NO: 2; or
(2) a recombinant protein produced by a method comprising: (a) integrating an insert with the nucleotide sequence SEQ ID NO. 1 in an expression vector; (b) transforming a host with the expression vector of step (a); (c) inducing the expression of the recombinant protein; (d) extracting the recombinant protein; and optionally (e) purifying the recombinant protein; or
(3) a protein that is a soluble isoform of interferon alpha and beta receptor subunit 2 (IFNAR2.3);
such that said multiple sclerosis is treated or ameliorated.
US Pat. No. 10,391,196

PREFABRICATED ALGINATE-DRUG BANDAGES

President and Fellows of ...

1. A method of making a bandage composition, comprising:(1) providing an alginate solution comprising a therapeutic agent;
(2) adding a woven mesh to said alginate solution;
(3) molding said alginate solution comprising the woven mesh into a desired shape;
(4) inducing a cryo-organized structure by freezing and lyophilizing said molded solution; and
(5) contacting said cryo-organized structure with a crosslinking agent to yield a bandage composition, wherein said bandage composition comprises a Young's modulus of 100 kiloPascals to 10,000 kiloPascals at room temperature.
US Pat. No. 10,392,479

PLATINUM COMPLEXES AND THEIR USE IN COMPOUNDS THAT CAN BE CROSS-LINKED BY A HYDROSILYLATION REACTION

WACKER CHEMIE AG, Munich...

1. A platinum complex of the formulaR33Pt{CpR45-r-t[(CR2)nSiR1oR2p]t[SiR7sR83-s]r}  (I)
where
Cp is a cyclopentadienyl radical,
n is an integer from 1 to 8,
o is 0, 1, 2 or 3,
p is 0, 1, 2 or 3, with the proviso that o+p=3,
r is 1, 2, 3, 4 or 5,
t is 0, 1, 2, 3 or 4, with the proviso that r+t?5,
s is 0, 1 or 2,
R each is the same or different and is hydrogen or a monovalent unsubstituted or substituted hydrocarbyl radical,
R1 each is the same or different and is a monovalent unsubstituted or substituted hydrocarbyl radical which is optionally interrupted by heteroatoms,
R2 each is the same or different and is a hydrolyzable group or an oxygen-bonded siloxy radical,
R7 each is the same or different and is a monovalent, unsubstituted or substituted, aliphatically saturated hydrocarbyl radical which may be interrupted by heteroatoms, or an oxygen-bonded siloxy radical,
R8 each is the same or different and is an aliphatically unsaturated, optionally substituted radical,
R3 each is the same or different and is a monovalent, unsubstituted or substituted, aliphatically saturated hydrocarbyl radical,
R4 each is the same or different and is a hydrogen atom, SiC-bonded silyl radical or an unsubstituted or substituted hydrocarbyl radical which may be interrupted by heteroatoms.
US Pat. No. 10,395,807

GRAIN-ORIENTED ELECTRICAL STEEL SHEET HAVING EXCELLENT MAGNETIC CHARACTERISTICS AND COATING ADHESION

JFE STEEL CORPORATION, T...

1. A grain-oriented electrical steel sheet provided on its sheet surface with a tension-imparting type insulation coating constituted with a coating layer A formed on a steel sheet side and mainly composed of an oxide and a coating layer B formed on the coating layer A and mainly composed of glass, characterized in that a ratio R (?B/?A) of a tension ?B to a tension ?A is within a range of 1.20-4.0, wherein:the tension ?A is a tensile stress applied to the steel sheet by the coating layer A as a result of a difference between the coefficient of thermal expansion of the steel sheet and the coefficient of thermal expansion of the coating layer A, and
the tension ?B is a tensile stress applied to the steel sheet by the coating layer B as a result of a difference between the coefficient of thermal expansion of the steel sheet and the coefficient of thermal expansion of the coating layer B.
US Pat. No. 10,391,197

SILVER CONTAINING WOUND DRESSING

ConvaTec Technologies Inc...

1. A wound dressing comprising gel-forming fibres having anti-microbial activity, comprising a first fibre, which is gel-forming and substantially insoluble in water having silver (I) cations bonded thereto and discoloring on exposure to light, and a second fibre, which is gel-forming and substantially free from silver, wherein the wound dressing comprises a uniform blend of the first fibre and the second fibre, said wound dressing comprising from 0.01 to 5.0 percent by weight of silver (I) cations based on a total weight of first and second fibres, whereby discoloration of the blend on exposure to light is lessened compared with discoloration on exposure to light of a batch of the first fibre having a same average amount of the silver (I) cations present as is present in the blend.
US Pat. No. 10,392,480

CATALYST CONTAINING AMIDINE GROUPS

SIKA TECHNOLOGY AG, Baar...

1. A method of catalyzing hydrolysis or condensation or both of a polymer containing silane groups, comprising contacting a catalyst with the polymer containing silane groups, wherein:the catalyst comprises at least one amidine of the formula (I)
Y-A-Z  (I)
where
A is a divalent hydrocarbyl radical which has 2 to 30 carbon atoms and optionally contains unsaturated components and optionally ether oxygen or secondary or tertiary amine nitrogen,
Y is NR8R9 where R8 and R9 are independently an alkyl radical having 1 to 8 carbon atoms, or together are an optionally substituted alkylene radical having 4 to 10 carbon atoms, and
Z is an amidine group bonded via a nitrogen atom,
where Y and Z are separated from one another by at least two carbon atoms, and/or
at least one reaction product of at least one amidine of the formula (I) with at least one functional compound,
wherein A is not a polyoxyalkylene radical and wherein the amidine of the formula (I) does not contain any nitrogen atom which is directly bonded to an aromatic ring or is part of a heteroaromatic ring system.
US Pat. No. 10,393,760

SPECIALIZED EXCITATORY SYNAPTIC PROTEIN BIOMARKERS OF PLASMA NEURONAL EXOSOMES FOR PREDICTION AND STAGING OF ALZHEIMER'S DISEASE

1. Method of diagnosing and treatment of Alzheimer's Disease (AD) comprising(a) obtaining a venous blood sample from a human patient;
(b) extracting from the venous blood sample synaptic proteins of neuronal pentraxin 2 (NPTX2), GluA4-containing glutamate receptor (AMPA4), neurexin 2? (NRXN2?), and neuroligin 1 (NLGN1),
(c) determining neuron-derived exosome (NDE) levels for each synaptic pair of (i) NPTX2 and AMPA4 of (b) and (ii) NRXN2? and NLGN1 of (b),
(d) comparing said NDE levels of each said synaptic pair of (c) with NDE levels of synaptic pairs of (i) NPTX2 and AMPA 4 and (ii) NRXN2? and NLGN1 obtained from the same human patient at a clinically meaningful earlier point in time or obtained, from a control subject known to not have cognitive losses, and detecting a decrease in NDE levels between the compared synaptic pairs; and
(e) administering to the human patient treatment for AD.
US Pat. No. 10,392,482

FIBER-REINFORCED RESIN MOLDING MATERIAL AND PRODUCTION METHOD THEREOF

Toray Industries, Inc., ...

1. A fiber-reinforced resin molding material comprising at least bundled aggregates of discontinuous reinforcing fibers and matrix resin, wherein said bundled aggregates of reinforcing fibers comprise both reinforcing fiber aggregates (A) which are formed by cutting continuous reinforcing fiber strands after fiber splitting, in which said strands are completely split into multiple bundles, and reinforcing fiber aggregates (B) having at least unsplit strand sections in which fiber splitting is incomplete, an incision originating from fiber splitting is present at least at one of both end portions of said reinforcing fiber aggregates (B), and a ratio of the weight of said reinforcing fiber aggregates (B) to the total weight of reinforcing fibers in said material is 5-50%.
US Pat. No. 10,393,762

MEANS AND METHODS FOR DIAGNOSING HEART FAILURE IN A SUBJECT

METANOMICS GMBH, Berlin ...

1. A method for diagnosing and treating heart failure in a subject comprising the steps of:a) determining, using mass spectrometry, in a sample of a subject suspected to suffer from heart failure the amount of at least one biomarker selected from the group consisting of Sphingomyelin (d18:1, C23:1), Sphingomyelin (d17:1,C24:1), and Sphingomyelin (d18:2, C23:0), wherein the sample is a blood, plasma, or serum sample;
b) comparing the amount of said at least one biomarker to a reference, whereby heart failure is diagnosed:
i) if the amount of said at least one biomarker is significantly decreased as compared to the reference when the reference is derived from a subject or group of subjects known not to suffer from heart failure or a calculated reference; or
ii) if the amount of said at least one biomarker is essentially identical to the reference when the reference is derived from a subject or group of subjects known to suffer from heart failure;
c) identifying the subject as having heart failure and in need of therapy therefor; and
d) treating the subject by administering at least one drug selected from the group consisting of: ACE inhibitors, Beta Blockers, AT-1 inhibitors, Aldosteron Antagonists, Renin Antagonists, Diuretics, Ca-Sensitizer, Digitalis Glykosides, polypeptides of the protein S100 family, and natriuretic peptides.
US Pat. No. 10,391,200

METHOD FOR IN VIVO HAIR MULTIPLICATION

HAIR SCIENCE INSTITUTE, ...

1. A cosmetic method for in vivo hair multiplication, comprising the steps of:(a) harvesting at least a part of a hair follicle in the anagen phase, said at least a part of a hair follicle comprising at least one hair follicular stem cell;
(b) after said harvesting, making at least two incisions along the longitudinal axis of said at least a part of a hair follicle;
(c) contacting said at least a part of a hair follicle of step (b) with a medium for at least 1 second; and
(d) implanting said at least a part of a hair follicle of step (c) into a recipient area of a subject;
wherein the incisions avoid the hair shaft per se, where no hair follicle material is present.
US Pat. No. 10,391,201

GENE THERAPY

OSPEDALE SAN RAFFAELE SRL...

1. A method of transducing a population of human haematopoietic stem and/or progenitor cells comprising the steps of:a) contacting the population of cells with cyclosporin A (CsA) at a concentration of about 5-50 ?M; and
b) transducing the population of cells with a HIV-1, HIV-2, FIV, BIV, EIAV, CAEV or visna lentiviral vector, wherein the vector does not comprise SIV capsid proteins;wherein transduction efficiency is increased in comparison to transduction in the absence of the CsA.
US Pat. No. 10,392,486

TRANSPARENT LAMINATE FILM

DAICEL CORPORATION, Osak...

1. A display having a surface with a maximum height of rolling circle waviness profile (WEM) in accordance with Japanese Industrial Standards (JIS) B0610 of 5 to 15 ?m and an arithmetic average roughness (Ra) of not less than 0.5 ?m.
US Pat. No. 10,392,742

BIOFINISHING SYSTEM

1. A process for biofinishing a cellulose-containing textile, comprising:(a) treating the cellulose-containing textile with a first GH45 cellulase having biofinishing activity; and
(b) treating the cellulose-containing textile with a second GH45 cellulase having biofinishing activity,
wherein the first GH45 cellulase or the second GH45 cellulase has at least 90% sequence identity to SEQ ID NO: 2, at least 90% sequence identity to amino acids 22-299 of SEQ ID NO: 4, at least 90% sequence identity to amino acids 22 to 294 of SEQ ID NO: 6 or at least 90% sequence identity to amino acids 22-293 of SEQ ID NO: 8.
US Pat. No. 10,391,205

POLYMER FOR MEDICAL DEVICE, MEDICAL DEVICE MATERIAL AND MEDICAL DEVICE PREPARED FROM THE MATERIAL, AND MONOMER COMPOSITION FOR POLYMER FOR USE IN PRODUCTION OF MEDICAL DEVICE

National University Corpo...

1. A polymer having a structural unit derived from a glycerol group-containing monomer, and a structural unit derived from an unsaturated monomer having a structure in which an organic group having a structure site having 4 or more continuously-bound carbon atoms is bound to an ethylenically unsaturated group; andsatisfying a glass-transition temperature of ?5° C. or less and/or a glass-transition temperature of ?25° C. or less at a saturated water content.
US Pat. No. 10,392,488

METHOD FOR PRODUCING EXPANDED THERMOPLASTIC ELASTOMER PARTICLES

BASF SE, (DE)

1. A process for production of expanded thermoplastic elastomer beads having an uninterrupted skin, said process comprising;a) impregnating a blowing agent into thermoplastic elastomer beads to give impregnated thermoplastic elastomer beads, the thermoplastic elastomer beads being surrounded by a gaseous medium that has an impregnating temperature Ta, wherein the absolute pressure of the gaseous medium is greater than ambient pressure, and wherein the thermoplastic elastomer beads are selected from thermoplastic polyester elastomers, thermoplastic copolyamides or thermoplastic polyurethanes, or mixtures thereof,
b) expanding the impregnated thermoplastic elastomer beads by exposing the thermoplastic elastomer beads to a pressure reduction at a first expanding temperature Tb to give expanded thermoplastic elastomer beads and
c) optionally a fusing step, wherein the expanded thermoplastic elastomer beads are fused together at a fusing temperature Tc to form at least one shaped part,
wherein the thermoplastic elastomer beads are made from amorphous thermoplastic elastomer, partly crystalline thermoplastic elastomer, or mixtures thereof, and the impregnating temperature Ta, the first expanding temperature Tb and the fusing temperature Tc each depend on the thermoplastic elastomer wherein,
i. if the thermoplastic elastomer is amorphous, the impregnating temperature Ta, the first expanding temperature Tb and the fusing temperature Tc are higher than a first limiting temperature TG-40, wherein the first limiting temperature TG-40 is 40° C. below the glass transition temperature TG according to DIN EN ISO 11357-2:2013-09 of the thermoplastic elastomer beads not being impregnated, or
ii. if the thermoplastic elastomer is partly crystalline, the impregnating temperature Ta, the first expanding temperature Tb and the fusing temperature Tc are higher than the glass transition temperature TG according to DIN EN ISO 11357-2:2013-09 of the nonimpregnated thermoplastic elastomer beads and lower than a second limiting temperature TS-5 which is 5° C. below the melting temperature TS according to DIN EN ISO 11357-3:2013-04 of the thermoplastic elastomer beads not being impregnated.